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 In the first part of this work, IspH, (E)-1-hydroxy-2-methyl-but-2-enyl 4-diphosphate 
reductase was studied. In most bacteria, apicomplexan parasites, and plants, the biosynthesis of 
the five carbon building blocks for terpenes is carried out by IspH. It is an essential enzyme not 
found in humans and a drug target for infectious diseases as well as herbicides. First, a new class 
of bacterial IspH we called IspH-RPS1, a fusion protein of IspH with ribosomal protein S1 
(RPS1), was characterized. Next, a new class of IspH inhibitors, one without diphosphate groups, 
was discovered.  
 The characterization of an IspH-RPS1 began with a bioinformatics analysis of the IspH 
protein family. ~400 sequences out of ~15,000 total sequences in a sequence similarity network 
of the IspH family were roughly double the length of a typical IspH protein. Most of these 
sequences contain an IspH domain fused to a RPS1 domain, and most are from obligate 
anaerobic bacteria. An IspH-RPS1 from Clostridium thermocellum was cloned, expressed, and 
found to be catalytically active. Mutagenesis studies showed that IspH catalytic activity was 
independent of the number of RPS1 domains fused to the IspH domain. The sequences being 
from obligate anaerobes coupled with the oxygen sensitivity of the Fe-S cluster in IspH suggests 
a possibility of IspH having a secondary function having to do with O2 detection. 
 Next, the way small molecules bind to IspH was studied with the view of gaining insight 
as to how new inhibitors might be designed. Until the publication of this work, all IspH 
inhibitors described in the literature contained diphosphate, which make the molecules highly 
charged and have poor cell penetration. Identifying new inhibitors may lead to the discovery of a 
cell active IspH inhibitor. Nuclear resonant vibrational spectroscopy (NRVS) and hyperfine 
sublevel correlation spectroscopy (HYSCORE), along with the examination of numerous IspH 
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and IspG structures revealed the importance of η1 σ-bonding of ligands to the fourth Fe in the 
4Fe-4S cluster. Additionally, a virtual screening campaign was carried out by collaborators at the 
University of California – San Diego, and enzymatic testing of the top hits identified a 
spirocyclic barbituric acid that exhibited a Ki of ~ 500 nM against Pseudomonas aeruginosa 
IspH. Synthesis of related molecules identified a benzyl containing analog with a Ki of ~ 3 µM 
against E. coli IspH. This was the first report of a non-diphosphate containing IspH inhibitor and 
this finding may help with the development of new IspH inhibitors exhibiting better cell 
penetration. 
In the second part of this work, the mechanism of action of bisphosphonates against 
cancer cell lines were studied. There are two types of bisphosphonates described in the literature: 
nitrogen containing (NBPs) and non-nitrogen containing bisphosphonates (NNBPs). These drugs 
are a major class of drugs typically used to treat bone resorption diseases like osteoporosis and 
Paget’s disease, but also have been found to be effective against cancer and bone metastasis. 
Bisphosphonates are proposed to target protein prenylation, the epidermal growth factor, or the 
adenine nucleotide translocase (ANT) via the formation in cells of two ATP-like molecules: an 
isopentenyl ester of ATP (ApppI) or an ATP analog with the terminal bridging oxygen replaced 
with CCl2 forming adenosine monophosphate (AMP)-clodronate. 
Given the high similarity of these metabolites to ATP, it seemed that these molecules 
might also inhibit kinases. ApppI and AMP-clodronate were screened against a panel of 369 
kinases and potent inhibition of some tyrosine kinases by AMP-clodronate was found, while 
ApppI activity against kinases were less active by ~200x or more. Analogs of AMP-clodronate 
were synthesized and found to be low nM kinase inhibitors. Bisphosphonate pre-prodrugs that 
are converted in cells to ATP-analogs were also synthesized and found to inhibit cell-signaling 
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pathways. This work provides clearer explanations behind the clinically observed effects of 
bisphosphonates, changes our thinking of bisphosphonate mechanism of action, and paves the 
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CHAPTER 1: INTRODUCTION 
 
1.1 The Non-Mevalonate Pathway and IspH. 
Isoprenoids are a large family of molecules that include essential molecules in all 
domains of life. Some examples are sterols in eukaryotes, which help to stabilize membranes, or 
polyprenyl chains that alter the cellular location and function of the protein1. In plants, 
carotenoids form protective pigments. In bacteria, undecaprenyl and decaprenyl diphosphates are 
used in bacterial cell-wall biosynthesis2, and menaquinone is used in the respiratory electron 
transport system3 (Figure 1.1A). Although these molecules are diverse in structure and function, 
they are all derived from two five carbon containing molecules: dimethylallyldiphosphate 
(DMAPP) and isopentenyldiphosphate (IPP) that are then condensed, cyclized, and tailored by a 
rich family of downstream enzymes to form various essential molecules4-5.  Although present in 
humans and bacteria, IPP and DMAPP are synthesized via different pathways. In eukaryotes, 
these building blocks are synthesized via the mevalonate pathway, but in most bacteria, 
apicomplexan parasites, and plants, DMAPP and IPP are synthesized in a different way, via the 
methylerythritol phosphate pathway (MEP) also known as the non-mevalonate pathway6. The 
non-mevalonate pathway begins with pyruvate and glyceraldehyde 3-phosphate (Figure 1.1B), 
and goes through seven enzymatic steps in order to generate IPP and DMAPP3. The enzymes in 
this pathway are essential for survival7, and as a result, there is interest in targeting these 
enzymes to treat infectious diseases. For example, fosmidomycin which inhibits the 1-deoxy-D-
xylulose-5- phosphate reductoisomerase (IspC/DXR),  reached Phase II clinical trials in 1985 for 
urinary tract infections7. 
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 After intermediates pass through six enzymatic steps, the final step to generate IPP and 
DMAPP is 1- hydroxy-2-methyl-2(E)-butenyl-4-diphosphate reductase or IspH.  Like the other 
enzymes in the non-mevalonate pathway, IspH is essential for the survival of most bacteria and 
malaria parasites, and it is also found in plant plastids8. IspH is an oxygen sensitive, 4Fe-4S 
cluster containing protein that catalyzes the 2H+/2e- reductive dihydroxylation of HMBPP into a 
~1:5 mixture of DMAPP and IPP9. The enzyme’s structure and function is well studied; IspH has 
a characteristic trefoil fold and the 4Fe-4S cluster resides in the center (Figure 1.2A).  
Its mechanism is a rather unique one. The consensus view is that IspH utilizes a bio-
organometallic route in which an allyl species binds to the Fe-S cluster, forming direct Fe-C 
interactions (Figure 1.2B). First, HMBPP binds to the oxidized Fe-S 2+ cluster to form an h1-
alkoxide. Next, a 1 e- reduction takes place to bring the cluster to the 1+ state forming a p-allyl 
complex, and the hydroxyl group rotates and forms to form a hydrogen bond with E126. 
Following that, the hydroxyl group is protonated by E126 and a water molecule is eliminated to 
form an h3-allyl anion complex with the 3+ Fe-S cluster. Finally, the anion is protonated and a 1 
e-  reduction forms the final products and returns the cluster to the 2+ state.  These findings were 
deduced from a many X-ray, mutagenesis, and spectroscopic studies8. In addition to the structure 
and function of IspH, the inhibition of IspH has also been studied, and some inhibitors are shown 
in Figure 2C.  Several substrate analogs as inhibitors have been discovered, and the mechanistic 
studies have also inspired the development of alkyne containing inhibitors, which bind to the Fe-
S cluster in a manner similar to the allyl species. 
1.2 A New Class of IspH and a New Class of IspH Inhibitors. 
Although the function and mechanism of IspH are now clearer, this work will show that 
there are still many unknown details regarding IspH’s function to be uncovered, and there may 
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be more ways to inhibit IspH to be discovered. In the first part of this work, a new class of IspH 
is described, whose discovery and characterization now present new questions on IspH’s 
function, namely, could it have a secondary function? By using bioinformatic methods to analyze 
the IspH protein family, several hundred IspH fusion proteins were identified. Examples of IspH 
fused to ribosomal protein S1 (RPS1) as well as IspH fused to UbiA (4-hydroxybenzoate 
octaprenyltransferase)-like protein are shown.  All of the IspH-RPS1 proteins are found in 
anaerobes, many found in the human gut, and some are found in pathogens such as Clostridium 
botulinum, C. tetani, and Fusobacterium nucleatum. Following the bioinformatic finding of these 
proteins, the initial cloning, expression, purification, activity, inhibition, mutagenesis and 
spectroscopic results on one IspH-RPS1 protein were performed10. The discovery of these new 
types of IspH and the patterns of their occurrence opens new avenues of research with regards to 
bacterial physiology. 
 In the second part of this work, a new class of IspH inhibitors is described. Several IspH 
inhibitors are described in the literature; some inhibitors are substrate mimics while others were 
designed to take advantage of the bio-organometallic mechanism of IspH8. However, all of the 
previously described inhibitors contain diphosphate which is necessary for binding of the ligand 
to the protein. This highly charged moiety limits cell penetration however, and so none of the 
inhibitors are active against cells. In the quest to identify cell active inhibitors, the second part of 
this work on IspH began with in silico screens of the ZINC library against IspH identified several 
hits. Enzymatic testing of those hits identified one spirocyclic barbituate with a Ki of ~ 500 nM 
against Pseudomonas aeruginosa IspH. Synthetic modification of the molecule identified a 
second analog with a Ki of ~ 3 µM against E. coli IspH11. These two inhibitors are the first 
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reports of an IspH inhibitor without the diphosphate moiety and may be optimized for greater 
potency and cell penetration. 
1.3 Bisphosphonate Mechanism of Action.  
Bisphosphonates are a major class of drugs used to treat osteoporosis, Paget’s disease, 
and cancer. They are a class of drugs containing a phosphorous-carbon-phosphorous bond that 
mimics diphosphate and binds to the bone surface. Once bound to the bone surface, these 
compounds can accumulate in high amounts into osteoclasts and cause apoptosis, thus slowing 
down bone resorption12. These compounds were first used in the clinic in the 1960s, but it was 
not until ~30 years later that the mechanism of action began to become clearer. The earliest 
bisphosphonates were simple analogs of pyrophosphate, with halogens, methyl, or alcohol 
substitutions on the bridging carbon. In the late 1980s, early 1990s, these bisphosphonates were 
found to be metabolized into ATP-like analogs (Figure 1.3A). These analogs form by the back 
reaction in aminoacyl-tRNA synthetases where adenosine monophosphate condenses with the 
bisphosphonate1. It was also found that these metabolites could accumulate in the cytosol of 
various cell types up to 1 mM13, and then in 2002, it was shown that these metabolites could 
inhibit the adenosine nucleotide translocase (ANT) in the mitochondria leading to cell 
apoptosis14. 
By the late 1990s, another type of bisphosphonates were developed, nitrogen 
bisphosphonates (NBPs), and these were found to be more potent than the first generation non-
nitrogen containing bisphosphonates (NNBPs). NBPs were found to inhibit farnesyl diphosphate 
synthase1 (FPPS), which catalyzes the condensation of DMAPP and IPP to form farnesyl 
diphosphate (FPP). FPP and a downstream isoprenoid geranylgeranyl diphosphate (GGPP) are 
essential for cell signaling and protein prenylation, thus inhibition of their formation leads to cell 
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death. Additionally, inhibition of FPPS causes IPP and DMAPP to pool up, promoting the 
formation of an isopentenyl ester of ATP (ApppI) and the dimethylallyl ester of ATP (ApppD). 
These esters of ATP were also found to be toxic, also inhibiting the ANT15 (Figure 1.3B). 
Bisphosphonates also have interesting tumor killing properties and anti-inflammatory 
effects in addition to their use in treating bone-resorption diseases. The interesting clinical 
observations prompted more research into how bisphosphonates, in particular NBPs, exert this 
action. A few avenues have been studied and proposed: NBPs can block tumor growth by 
activating g,d-T cells, which are a type of lymphocytes that play an important role in immunity, 
via the accumulation of IPP1. In addition to FPPS, NBPs have also been proposed to directly 
inhibit the epidermal growth factor receptor16. However, there is a dose discrepancy between the 
IC50 values of bisphosphonates in enzymatic assays versus cell killing assays (~500µM vs. ~50 
µM). However, this investigation into kinases inspired a different hypothesis: since ApppI, 
ApppD, and AMP-clodronate have a high similarity to ATP, we hypothesized that these 
molecules might inhibit kinases, rather than the free acid bisphosphonate. 
ApppI and AMP-clodronate (AppCCl2p) were screened against a panel of 369 kinases 
and AppCCl2p was found to have a selectivity for tyrosine kinases at low nM levels while ApppI 
had a selectivity for Ser/Thr kinases, but only at low µM levels. Following the kinome screen 
and a more accurate 10-point dose response assay, the synthesis of pre-prodrugs of 
bisphosphonates, cell testing, western blot analysis, mitochondrial respiration assays, FPPS and 
geranylgeranyl diphosphate synthase (GGPPS) inhibition, ApppI formation assays, and 






Figure 1.1. A) Structures of molecules discussed in text. UPP = undecaprenyl 
pyrophosphate. B) The non-mevalonate pathway begins with pyruvate and G3P 
(glyceraldehyde 3-phosphate) and goes through six enzymatic transformations to reach the 





Figure 1.2. A) The structure of E. coli IspH (PDB: 3KE8). The 4Fe4S cluster can be 
seen in the center of the trefoil structure.  B) The bio-organometallic mechanism of 




























Figure 1.3. Overview of bisphosphonate mechanism of actions. A) Non-nitrogen 
containing bisphosphonates like clodronate are metabolized into ATP-like analogs 
(AppCCl2p) and inhibit the ANT (previous work) as well as kinases, but at stronger 
levels (this work). B) Nitrogen containing bisphosphonates inhibit FPPS, causing a 
buildup of IPP and DMAPP which form ApppI and ApppD. ApppI and ApppD inhibit 
the ANT and kinases, but much at much weaker levels than zoledronate FPPS inhibition. 
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CHAPTER 2: ISPH-RPS1 AND ISPH-UBIA: "ROSETTA STONE" PROTEINS 
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2.2 Introduction 
The methylerythritol phosphate pathway is responsible for the production of the terpene 
building blocks dimethylallyl diphosphate (DMAPP, 1, Scheme 1.1) and isopentenyl 
diphosphate (IPP, 2) in most bacteria, apicomplexan parasites, and plants. Its component 
enzymes are all essential for survival, so there is interest in their inhibition1-2 for the development 
of drugs to treat infectious diseases, such as malaria and tuberculosis, with fosmidomycin3, 
which inhibits deoxyxylulose 4-phosphate reductoisomerase, having reached clinical trials for 
malaria4. In addition, targeting the pathway could be of use for herbicide development. IspH, 
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(E)-1-hydroxy-2-methyl-but-2-enyl 4-diphosphate (HMBPP, 3) reductase, also known as LytB 
(but not to be confused with the N-acetylglucosaminidase LytB from Streptococcus spp.), is the 
last enzyme in the pathway5. IspH is a 4Fe-4S cluster-containing protein6 that catalyzes the 
2H+/2e- reductive dehydroxylation of HMBPP into a ~1:5 mixture of dimethylallyl diphosphate 
and isopentyl diphosphate. Its structure and mechanism of action have been studied extensively, 
both experimentally7-13 and computationally14-16, and several inhibitors have been developed7. 
The mechanism of action is remarkable and the consensus view now is that IspH utilizes a bio-
organometallic mechanism in which an allyl species binds to the Fe-S cluster14-16. 
Despite their now well-known role in isoprenoid biosynthesis, IspHs (known as LytBs at 
the time) from E. coli and Campylobacter jejuni were first identified and investigated almost 20 
years ago in studies of the so-called “stringent response”, in bacteria17-18. The stringent response 
is a stress response that can arise from diverse insults and is aimed at limiting growth to promote 
survival. An IspH mutant E. coli strain WV718 induced the stringent response and exhibited a 
penicillin-tolerant phenotype at restrictive temperatures (42 oC). This phenotype could be 
complemented by wild-type E. coli IspH or C. jejuni IspH17, but not by a C. jejuni IspH Q265H 
mutant and it was proposed that the wild-type IspH could interact “directly or indirectly” with 
RelA18. RelA is an enzyme that has been shown to bind to the bacterial ribosome19 and is 
responsible for biosynthesis of the alarmone, (p)ppGpp, guanosine tetraphosphate (or 
pentaphosphate), the key regulator involved in the bacterial stringent response20. In addition, 
RelA is an emerging central regulator of multidrug tolerance and persistence21. If the interaction 
between IspH and RelA were disrupted, the stringent response would be induced.  
In other work it has been noted that that some bacterial proteins appear to contain a 
fusion in which IspH is linked to another ribosomal protein, RPS1, the ribosomal protein small 
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(30S ribosome) protein 122-23. Fusion hybrids are often found when two individual proteins have 
some related activity and are called "Rosetta stone" proteins24-25 and RPS1-IspH is given as one25 
example, although the functional relatedness of the 2 domains has not been proposed. Here, we 
report initial cloning, expression, purification, activity, inhibition, mutagenesis and spectroscopic 
results on one IspH-RPS1 protein. In addition, we report that several other proteins form fusion 
hybrids with IspH, one of which appears to be a functionally related prenyl synthase. 
2.3 Results and Discussion 
2.3.1 IspH-RPS1: A Rosetta Stone Protein Present in Many Gut Bacteria, and Some 
Human Pathogens.  
We first investigated the network of IspH family proteins by using the Enzyme Similarity tool 
from the Enzyme Function Initiative (EFI-EST; www.enzymefunction.org) to generate a 
sequence similarity network for IspH family proteins, and visualized the results by using 
Cytoscape26-28. An overview of 15,660 IspHs is shown in Figure 2.1. Most can be sorted into 
clusters based on the phylum and class of the organism. In a network with an expectation value 
of 10-120 , the major clusters shown in Figure 2.1 are as follows: a, Gammaproteobacteria (dark 
cyan, upper left) and Betaproteobacteria (blue, lower right); b, Alphaproteobacteria (cyan); c, 
Firmicutes (purple); d, Firmicutes (with very long sequences, red); e, Bacteroidetes (yellow); f, 
Actinobacteria (orange); g, Cyanobacteria and plants (green); h, Apicomplexa (pink, genus 
Plasmodium, the malaria parasites) and i, Desulfobacterales (brown, an order of 
Deltaproteobacteria).      
What is of particular interest about these bioinformatics results is that, unlike most 
bacterial IspHs—which typically have ~300 residues (e.g. E. coli, N=316 residues, and Aquifex 
aeolicus, N=297 residues)—the IspHs found in cluster D (and a few isolated nodes) are much 
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larger, with N~600-850 residues. In most cases this is due to a fusion with several ribosomal 
protein S1-like tandem repeats, found in the ribosomal protein S1 (RPS1) in the 30S subunit of 
the bacterial ribosome. The basic IspH-RPS1 architectures are shown schematically in Figure 
2.1j. Notably, essentially all of the organisms that have the IspH-RPS1 fusion are anaerobic 
bacteria. Among the 447 IspH-RPS1 sequences, 157 are from anaerobes. The other 290 are not 
annotated, but are primarily from anaerobic species. As shown in the zoomed-in view of the 
IspH-RPS1 network (Figure 2.2), the majority of the IspH-RPS1s are from Firmicutes, low G+C 
gram-positives, including many members from the genus Clostridium. They include pathogens 
such as C. tetani and C. botulinum (the causative agents of tetanus and botulism, respectively), as 
well as the industrially valuable strain, C. acetobutylicum. A few IspH-RPS1s are from gram-
negatives and typically contain 6 S1 repeats, Figure 2.1j, one example being Fusobacterium 
nucleatum. This organism plays a role in periodontal disease as well as being associated with 
colorectal carcinoma29-30 where it is involved in protecting tumors from immune system (NK 
cell) attack31. We also found that 37% of the IspH-RPS1s are present in the human gut, examples 
being Clostridium sp. SS2-1, Eubacterium hallii, Subdoligranulum variabile, Clostridium 
leptum,  Coprococcus eutactus, Clostridium sp. L2-50, Anaerotruncus colihominis, and 
Clostridium asparagiforme, the first two organisms being the 7th and 9th most abundant gut 
bacteria32.  
As noted in the book chapter by Pellegrini and Graeber25, the IspH-RPS1 fusion hybrids 
are thought to be examples of Rosetta stone proteins, functionally-related fusion proteins, rather 
than having arisen from random fusion events. However, there have been no proposals as to what 
the non-IspH function might be, rather, it is the high occurrence of IspH-RPS1 hybrids that is 
suggestive of functional relatedness.  
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2.3.2 IspH Forms Other Fusion Hybrids.  
Inspired by the observation of large numbers of IspH-RPS1 fusion proteins, we next 
examined the sequences and conserved domains of all IspHs in the sequence similarity network. 
In addition to the IspH-RPS1 fusions and the plant/protozoan IspHs (that appear to have an N-
terminal plastid-localization domain), there are five other types of IspH fusion annotated (Figure 
2.1k; Figure 2.3). The most abundant fusion is between IspH and a putative prenyltransferase, 
typically annotated as a UbiA (4-hydroxybenzoate octaprenyltransferase) family protein. There 
were 47 such sequences found, primarily in the gram-negative sulfate-reducing bacteria 
Desulfobacterales (cluster i in the Cytoscape network, brown, Figure 2.1i) in which the UbiA-
like prenyltransferase domain was fused to the C-terminus of IspH, Figure 2.1k. UbiAs form a 
superfamily of proteins, typically thought to contain ~9 trans-membrane helices, and the X-ray 
structure of UbiA has recently been reported33. The function of the UbiA-annotated domain in 
the IspH-UbiAs, categorized as PT_UbiA_5, is unknown, However, it has been reported that 
ubiquinones are not detected in sulfate-reducing bacteria34; that menaquinone-7 is the major 
respiratory quinone in these organism; and a separate UbiA/MenA is evident in their genomes. It 
seems likely, nevertheless, that the UbiA domain is involved in prenyl transferase activity, not 
least since there are two "DXXXD" repeats present, typical of prenyl synthases and transferases, 
and the fact that IspH appears to be fused to a second prenyltransferase would be of interest since 
it suggests that the fusion may be functionally significant-a true Rosetta stone protein. In 
addition, the hybrid protein would likely be membrane-bound. Four other types of fusion were 
found only in single species (or several strains of the same species): CMP kinase; helicases; 
fructose bisphosphatase and UDP/PNP phosphorylase (Figure 2.3a-d). Plus, in a recent report35, 
IspHs from a cyanobacterium and a plant, photosynthetic organisms, were proposed to have an 
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extra N-terminal conserved domain and a conserved Tyr (Figure 2.3e), to protect the enzyme 
from high oxygen levels during photosynthesis, although this domain appears to be a simple 
IspH modification.  
2.3.3 Organization and Structure Prediction for IspH-RPS1 and IspH-UbiA.  
We next sought to begin to investigate the possible structures of the IspH-RPS1 and 
IspH-UbiA hybrids. RPS1s from most gram-positive bacteria (e.g. Bacillus subtilis) contain 4 
S1-like repeats, Figure 2.1j (top), while RPS1s from gram-negatives (e.g. E. coli) typically 
contains 6 S1-like repeats, Figure 2.1j (bottom). In E. coli, the first two repeats are used for 
ribosome binding36, the last repeats for mRNA binding during translation-initiation. There have 
been no X-ray structures of any IspH-RPS1s reported. The structures of small bacterial and a 
protozoal IspH have, however, been reported8, 37, and by way of example, we show that of the E. 
coli protein in Figure 2.5a, together with that of the P. falciparium protein (N=318, the 
apicoplast-targeting domain being  absent), in Figure 2.5b38.  
Both the E. coli and P. falciparum structures are characterized by a trefoil/clover-leaf 
arrangement of α/β domains with the catalytic 4Fe-4S cluster at the center of each structure, 
linked to the protein via 3 Cys thiols. Substrate, inhibitor or water molecules occupy the 
remaining coordination sites. By way of comparison, a computational (Phyre2  program39) 
structure prediction of the Clostridium thermocellum IspH-RPS1 protein is shown in Figure 2.5c. 
The trefoil-like IspH domain is well defined, plus there are four more (and less) defined RPS1 
domains (which are based on the solution NMR structures of individually expressed RPS1 
domains)23.  
A Phyre2 structure prediction of the Desulfobacula toluolica (a marine, aromatic 
compound-degrading, sulfate-reducing bacterium) IspH-UbiA is shown in Figure 2.5d. The 
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UbiA domain is essentially that seen in the X-ray structure of Aeropyrum pernix UbiA33 (the 
template used by the Phyre2 program) and the 3 conserved Cys (yellow spheres) in the IspH 
domain and the two Asp rich (DXXXD) sites in the UbiA domain (purple spheres) can be readily 
identified. The UbiA domain is predicted to contain 9 trans-membrane helices, and the IspH 
domain presumably lies on the cytoplasmatic side of the membrane, as shown in Figure 2.5d, 
although in most predicted structures this localization was variable. 
In addition to the 3 essential Cys found in all IspH family proteins, involved in 
coordinating the 4Fe-4S cluster, IspH-RPS1s contain significantly more Cys than do the more 
conventional IspHs:  7.4 versus 4.8 on average (in the IspH domain), and some strains 
(Clostridium sp. CAG: 678; Mogibacterium sp. CM50) contained as many as 14 Cys. The high 
cysteine content is probably related to the observation that most of the species are anaerobes, 
since it has been pointed out that cysteine depletion occurs on a proteome-wide scale on moving 
from anaerobic to aerobic unicellular organisms40. The range of Cys content in the IspHs is, 
however, much larger than the proteome-wide average.      
At present, there is no information as to whether there are important functional 
consequences of the IspH-RPS1 (or other) fusions. Thus, as a first step toward answering that 
question, we next sought to express an IspH-RPS1, the most abundant IspH fusion protein, in 
order to form the basis for future studies of structure and function.  
2.3.4 Cloning, Expression, Purification and Catalytic Activity of IspH-RPS1.  
Since we did not find any other ispH or rps1 genes in the organisms that harbor ispH-
rps1, it is almost certain that the IspH domain makes IPP/DMAPP, since mevalonate pathway 
enzymes are absent in the genome. We first sought to see if IspH-RPS1 could be expressed and 
purified in an active form, catalyzing IPP/DMAPP formation from HMBPP. We attempted 
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expression of IspH-RPS1s from three bacteria: F. nucleatum, C. acetobutylicum, and C. 
thermocellum. Initial trials with F. nucleatum and C. acetobutylicum resulted in low expression 
yields or inactive protein, although UV-Vis spectra clearly indicated the presence of a Fe-S 
cluster with C. acetobutylicum IspH-RPS1. Fortunately, active (in an HMBPP reduction assay) 
C. thermocellum (Cth) IspH-RPS1 could be readily expressed in E. coli with moderate yields (~3 
mg/L). C. thermocellum is an anaerobic, thermophilic bacterium that is of commercial interest 
since it catalyzes the direct conversion of crystalline cellulosic biomass into ethanol41.  
CthispH-rps1 encodes a single polypeptide of 694 residues and contains 4 S1-like repeats 
in the RPS1 domain. It was purified as an 81.2 kDa protein (with an N-terminus His6-tag) and its 
identity was verified by MALDI-TOF with an error of < 0.1% (Figure 2.6a, [M1+H]+, expected: 
81309.0, found: 81233.9). However, there was poor iron-sulfur cluster incorporation, typically 
~10%, even when co-expressed with the IscS protein42 that catalyzes cluster formation. We thus 
next used an in vitro reconstitution method with an expressed and purified IscS. The UV-Vis 
absorption spectrum of the reconstituted CthIspH-RPS1 protein at 410 nm, Figure 2.6b, is 
consistent with the presence of an "oxidized" [Fe4S4]2+ cluster. This could be reduced by 
dithionite to the reduced [Fe4S4]+ cluster, as found with other IspH proteins43.  
We then examined the catalytic activity of CthIspH-RPS1 in the conversion of HMBPP 
into DMAPP and IPP by using the methyl viologen assay described previously44. As shown in 
Figure 2.6c, the enzyme has a kcat of 56 min-1 and a Km of 15 µM, at room temperature. The kcat is 
very close to the value found with IspH from the thermophile Aquifex aeolicus while the Km is 2-
fold larger (kcat=1.0 s-1; Km=7 µM)7. Substrate consumption and product formation were also 
confirmed by LC-MS (Figure 2.7) and NMR analysis. So, an IspH-RPS1 can be expressed from 
a thermophile and its activity is similar to that of IspH from another, "IspH-only", thermophile. 
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2.3.5 Truncation Mutants: Effects on Activity and on 4Fe-4S Cluster-Binding.  
In order to find out whether the presence of the RPS1 domain had any effects on the 
catalytic activity of CthIspH-RPS1, we made truncation mutants containing 0, 1, 2 or 3 S1-like 
repeats (called here D0, D1, D2, D3; cartoon in Figure 2.6d). As shown in Figure 2.6e, these 
truncation mutants had almost the same activity as the wild-type CthIspH-RPS1 which contains 
4 S1-like repeats, indicating that the RPS1 domain is not essential for IspH catalysis, at least in 
this in vitro assay. 
We then investigated the 9 GHz EPR spectra of wild-type and truncation mutants of 
CthIspH-RPS1, Figure 2.6f, to see if there were any obvious differences in cluster electronic 
structure, due to RPS1 binding. The wild-type CthIspH-RPS1 spectrum (Figure 2.6f, pink) had g 
values of [5.0, 2.022, 1.910, 1.896, 1.826], due to a mixture of signals from S = 3/2 and S = 1/2 
species. By way of comparison, higher-spin species were not as obvious in E. coli IspH (Figure 
2.6f, yellow), and the g values at g~2 were also slightly lower [1.998, 1.900, 1.873, 1.791]. The 
mutants all exhibited essentially the same EPR spectra as the wild-type C. thermocellum protein. 
We also made (though not by design) a very short C. thermocellum IspH (residues 1-171; 
"Cth171") in which the C-terminal "leaf" of the cloverleaf was excised. Although inactive and 
missing the third essential Cys, the protein still bound a reducible Fe/S cluster and had an EPR 
spectrum very similar to that of the other IspHs, as shown in Figure 2.6g.  However, unlike the 
other unliganded IspHs, Cth171 exhibited just the strong signal in the g~2 region, and the spectra 
did not change upon ligand binding, Figure 2.6g. Apparently, 3 Cys residues are not essential for 
cluster binding, but are for ligand binding. 
2.3.6 IspH-RPS1 Inhibition and a Comparison with Other IspHs.  
We next investigated the inhibition of CthIspH-RPS1 catalytic activity with the inhibitors 
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(4-12) developed previously7, 45, as well as a new compound (13).  The interest here is that it 
might be possible to develop compounds that specifically inhibit F. nucleatum cell growth, 
reinstating, perhaps, the cytotoxicity of NK cells against colorectal carcinomas29-31. 
Structures of the compounds tested are shown in Figure 2.8a and consist of various 
alkyne and pyridine diphosphates and phosphonates. Representative dose-response inhibition 
curves are shown in Figure 2.8b. These and other inhibition results are summarized in Figure 
2.8a together with Aquifex aeolicus IspH inhibition results. As a class, the acetylenes were the 
most potent inhibitors. The best inhibitor for CthIspH-RPS1 was the alkynyl compound 5, which 
had an IC50 of 3.3 µM. Compound 5 was also the most potent alkyne inhibitor for AaIspH, where 
it had the lowest IC50, 0.45 µM. The pyridine-containing compounds were, in general, weak 
inhibitors. Interestingly, a novel alkynyl thioester compound (i.e. with a P-S bond), 13, was very 
active against CthIspH-RPS1, compared to the ester compound 11. This thioester feature could 
potentially be useful in developing more drug-like leads that are resistant to hydrolysis, although 
pro-drugs will likely be needed for good cell penetration.  
To investigate IspH-RPS1 ligand-protein interactions in more detail, we obtained 9 GHz 
EPR spectra of liganded (the acetylene 4, the pyridine 8, and the thiolo -diphosphate 13), reduced 
CthIspH-RPS1, Figure 2.8c. Upon binding of the alkynes 4 or 13, the signal from the higher-spin 
species in the unliganded spectrum disappeared and the signal intensity of the spin S = 1/2 
species increased, with g values of [2.099, 2.012, 1.999] in the case of 13, similar to the values 
found with the alkyne inhibitors reported previously, bound to EcIspH and AaIspH7. Pyridine 
compounds such as 7-10 are another class of IspH inhibitors, but these all had only weak activity 
against CthIspH-RPS1, resulting in a significant amount of unliganded signal in the EPR 
spectrum of 8, despite the ligand being present in a 20-fold excess.  
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2.3.7 IspH-RPS1 Binds to E. coli Transcription Termination Factor Rho.  
A surprising observation during protein expression and purification was that when 
heterologously expressed in E. coli, CthIspH-RPS1 always co-purified with a protein of 46 kDa, 
as seen in the MALDI spectrum in Figure 2.6a. This protein (M2, Figure 2.6a) bound strongly 
enough to CthIspH-RPS1 that it co-purified with a CthIspH-RPS1 construct containing both a 
His-Tag and a Strep-Tag, in a two-step affinity chromatographic purification. The binding 
partner was subsequently found to be the E. coli transcription termination factor Rho through 
protein MS fingerprint analysis (Figure 2.9a), with a sequence coverage ratio of 69%. The Rho 
factor is a helicase that unwinds the DNA-RNA junction during transcription termination and has 
a strong binding affinity for nucleotides46-47. It seemed possible that the binding between 
CthIspH-RPS1 and EcRho might also be mediated by nucleotide binding and indeed, we found 
that Rho could be dissociated from CthIspH-RPS1 by washing the Ni-NTA resin with a 0.5 mM 
(CT)4 DNA oligomer, a reported Rho binder in an X-ray study48 (Figure 2.9b). It is also of 
interest that there is an actual (i.e., annotated) IspH-helicase fusion protein, in Bacteroidales 
bacterium CF, Figure 2.3b.  
2.3.8 Possible Roles of IspH-RPS1 and IspH-UbiA.  
The roles of the IspH fusions in IspH-RPS1 and IspH-UbiA remain to be determined. 
What is, however, clearly of interest is that there are hundreds of anaerobes that contain IspH-
RPS1 hybrids, many are in the human gut, and some are pathogens or carcinogens. The 
environments of these bacteria and the chemistry of the 4Fe-4S clusters suggests, perhaps, an 
additional role for the IspH domain as e.g. an oxygen or iron sensor, or in the stringent response. 
In addition, the very observation that IspH-RPS1 proteins exist supports previous ideas derived 
from work with E. coli (that lacks the RPS1 fusion) that the IspH domain might bind close to 
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RelA when IspH-RPS1 binds to the ribosome, Figure 2.10. Combining these results and ideas 
with the results of MS, EM and microbiological studies17-19, 36, we propose that the 4Fe-4S 
cluster might act as a “switch” to probe iron or oxygen levels, affecting RelA activity and the 
stringent response, a regulatory role of a 4Fe-4S cluster containing protein that would be 
reminiscent of the fumarate-nitrate reductase regulatory protein, FNR49, or perhaps of aconitase, 
another 4Fe-4S protein that has recently been found as a fusion with another ribosomal protein, 
bL2150.  
With IspH-UbiA, there are fewer species (47) than found with the IspH-RPS1 hybrids 
(447) but this is a large number (versus that expected for random fusions, <124). Again, all are 
found in anaerobes, so IspH might (again) act either as a sensor, or, perhaps more likely, the 
UbiA domain might localize IspH to the cell membrane, with IspH facilitating UbiA-like-protein 
product formation by providing high local levels of IPP/DMAPP (and hence, down-stream 
prenyl diphosphates). We attempted expression of IspH-UbiA fusion proteins from several 
sulfate-reducing bacteria: Desulfobacterium autotrophicum, Desulfobacca acetoxidans and 
Thermodesulfatator altanticus, but only succeeded in producing modest levels of IspH together 
with a UbiA domain fragment, most protein being truncated and appearing in inclusion bodies. 
The observation of several other fusion hybrids, Figure 2.4, could be the result of random events, 
however, it is of interest that in every case, the IspH partner is involved in phosphorus 
metabolism: a helicase, kinase, phosphatase or a phosphorylase.  
2.4 Conclusions  
Overall, the results reported here are of interest since they show that active IspH-RPS1 
proteins can be expressed, and inhibited, of potential interest in the context of understanding the 
biology underlying IspH gene fusions, as well as in anti-infective and even anti-cancer drug 
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discovery. There are many hundreds of organisms containing IspH-RPS1, about 37% being 
human gut bacteria. Some of these are in pathogens such as Clostridium tetani, Clostridium 
botulinum, and in Fusobacterium nucleatum, an oral pathogen that is also being linked to colon 
carcinoma. We also found that there are ~47 IspH-UbiA hybrids, all in sulfate-reducing bacteria, 
as well as smaller numbers of other IspH hybrids. We cloned, expressed and purified active 
IspH-RPS1 from Clostridium thermocellum and found that it had similar activity to IspH from 
another thermophile, Aquifex aeolicus. The IspH-RPS1 protein contains IspH fused to 4 RPS1 
repeats: removal of 1, 2, 3, or 4 of these domains had no effect on IspH catalytic activity. We 
investigated the inhibition of C. thermocellum IspH catalytic activity (conversion of HMBPP to 
DMAPP and IPP) by a series of alkyne and pyridine diphosphate and related inhibitors finding 
most potent activity with a novel alkyne thiolo-diphosphate, and the profiles of activity against 
both C. thermocellum and A. aeolicus were very similar. We also found that IspH-RPS1 bound to 
an E. coli protein, Rho, a helicase, and that there was evidence for an IspH-helicase hybrid, in 
Bacteroidales bacterium CF. With IspH-UbiA, we were not successful in expressing full length 
active protein, but the observation of such hybrids is still intriguing given that both components 
are likely to be involved in isoprenoid biosynthesis. The IspH-UbiA hybrid is very likely to fit 
the functional definition of a Rosetta stone protein in which there are two domains that act in the 
same metabolic pathway. IspH makes DMAPP and IPP, and UbiA-like proteins utilize a diverse 
range of prenyl diphosphates. With IspH-RPS1, there are many fusion hybrids reported, but the 
functional-relatedness of the two domains is less clear. However, since RPS1 proteins bind close 
to the RelA binding site on the bacterial ribosome, a role for IspH-RPS1 in the bacterial 
stringent-response is a possibility, consisted with previous suggestions of a IspH-RelA 
interaction, although further work will be required in order to fully understand the mechanism of 
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action of both hybrids. 
2.5 Materials and Methods 
2.5.1 Sequence similarity network.  
The sequence similarity network for the IspH family proteins (InterPro number 
IPR003451) was generated by using the Enzyme Function Initiative Enzyme Similarity Tool 
(EFI-EST, www.enzymefunction.org). An expectation-value of 10-120 was used to construct the 
network, which was then visualized by using Cytoscape 3.2.1. A single node represents 
sequences with at least 90% identity, while each edge joins sequences that share an e-value of 
10-120 or smaller.  
2.5.2 Cloning, protein expression, and purification. 
CthispH-rps1 and its mutants were amplified from the genomic DNA of Clostridium 
thermocellum strain VPI 7372 [ATCC® 27405TM] by polymerase chain reaction. The 
amplification product was digested with SacI-HF and SalI-HF (New England Biolabs, MA) and 
cloned into the pET-28a (+) vector (Novagen, WI). The plasmid with the correct insert was 
transformed into E. coli BL21-CodonPlus (DE3)-RIPL competent cells (Agilent, CA). For 
protein expression, six liters of LB broth supplemented with 25 mg/mL kanamycin and 17 
mg/mL chloramphenicol were inoculated with a 0.5% overnight culture and grown at 37 °C to an 
O.D.600 of 0.6-0.8. Protein expression was induced by addition of isopropyl β-D-1-
thiogalactopyranoside to a final concentration of 1 mM and the cultures were grown at 28 °C for 
a further 24 hrs.  The cells were then harvested and stored at -80 °C until further use. CthIspH-
RPS1 and all mutants were purified by using column chromatography employing a Ni-NTA 
HispurTM resin (Fisher, NY), according to the manufacturer’s instructions. Briefly, cell pellets 
were thawed and suspended in the loading buffer (5 mM imidazole, 50 mM Tris/HCl, 150 mM 
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NaCl, pH = 8.0) containing protease inhibitor cocktail tablet (Roche) and lysed by sonication. 
The cell debris was discarded after centrifugation and the clear cell lysate was loaded onto the 
resin. The resin was then washed (50 mM imidazole, 50 mM Tris/HCl, 150 mM NaCl, pH = 8.0) 
and the desired protein eluted (300 mM imidazole, 50 mM Tris/HCl, 150 mM NaCl, pH = 8.0). 
Imidazole was removed by dialysis against storage buffer (50 mM Tris/HCl, 150 mM NaCl, 
1mM DTT, 5% glycerol, pH = 8.0). The molecular weight of wild-type CthIspH-RPS1 was 
confirmed with MALDI-TOF (Bruker UltrafleXtreme, Boston, MA) mass spectrometry. Purity 
of the proteins was checked with SDS-PAGE. Protein concentrations were determined by using 
the Bradford assay. The concentrations of the [Fe4S4]2+ clusters were measured by using UV-Vis 
spectroscopy. The extinction coefficient at 410 nm was taken to be 15000 M-1 ·cm-151. 
2.5.3 Fe-S cluster reconstitution. 
The Fe4S4 cluster of CthIspH-RPS1 and its mutants was reconstituted by using purified 
Azotobacter vinelandii IscS protein. AvIscS was expressed from a plasmid which was the kind 
gift from Professor James A. Imlay. Typically, as-purified IspH-RPS1 was concentrated to ~2 
mL (~50-100 µM), degassed by bubbling nitrogen through the solution, transferred into an 
anaerobic chamber (Coy Labs, Grass Lake, IL), then stirred gently in the chamber overnight in 
order to equilibrate with the inert atmosphere. To the gently stirred protein solution was added 
0.5 mM Fe(NH4)2(SO4)2, 2.5 mM L-cysteine, 5 mM DTT and ~0.1 µM IscS. The reaction was 
incubated for several hours until Fe4S4 incorporation was satisfactory, taken to be an A410/A280 
ratio of ~0.4. The resulting protein solution was then centrifuged to remove any precipitate, 
desalted by using a PD10 column (Agilent, CA) and concentrated as necessary. IscS was not 
removed from the sample since it represents only ~0.1% of the total protein.  
2.5.4 Enzyme kinetics and inhibition assay.  
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The CthIspH kinetics and inhibition assays were performed by using the methyl viologen 
method described previously44. The final assay solution contained 40 nM enzyme, 50 µM 
HMBPP, 40 µM dithionite and 2 mM methyl viologen. The reactions were monitored at 606 nm. 
Km and kcat were fitted by using a Michaelis–Menten relation in Origin 9.1. The extinction 
coefficient for the methyl viologen radical cation at 606 nm was taken to be 13700 M-1 ·cm-152. 
2.5.5 Electron paramagnetic resonance (EPR) spectroscopy. 
All sample preparation procedures were carried out in an anaerobic chamber. 
Reconstituted and desalted CthIspH-RPS1 was concentrated to ~0.3-0.4 mM and 20 equivalents 
of Na2S2O4 and the ligand of interest, added. Samples (and no-ligand controls) were incubated 
for 30 min and then transferred into an EPR sample tube. EPR experiments were performed at X-
band (9 GHz) using a Varian E-122 spectrometer together with an Air Products (Allentown, PA) 
helium cryostat. Spectra were obtained at 10K at a 1 mW power level. 
2.5.6 Protein fingerprint analysis.  
The identity of the E. coli transcription termination factor Rho was assigned by protein 
fingerprint analysis in the Protein Science Facility at the University of Illinois at Urbana-
Champaign. Briefly, the sample containing the unknown protein was trypsin-digested and the 
resulting mixture analyzed by using electrospray ionization (ESI) tandem mass spectrometry in 
positive ion mode. The results were compared against a protein database using the Mascot 
program53.  
2.5.7 Synthetic protocols.  
All reagents were purchased from Aldrich (Milwaukee, WI). The purity of compounds 
investigated were confirmed by 1H, 13C and 31P NMR spectroscopy at 400 MHz or 500 MHz 
performed on Varian (Palo Alto, CA) Unity spectrometers. High-resolution mass spectra were 
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obtained at the University of Illinois Mass Spectrometry Laboratory. Cellulose thin layer 
chromatography (TLC) plates were visualized by using iodine or a sulphosalicylic acid-ferric 
chloride stain. The syntheses and characterization of 4–12 were described previously45. 
2.5.8 4-Hydroxybut-2-ynyl-S-thiolodiphosphate (13).  
Tris-(tetra-n-butylammonium)thiodiphosphate was prepared using a literature 
procedures54. 1-Chloro-4-hydroxy-2-butyne (52 mg, 0.5 mmol) in CH3CN (0.5 mL) was treated 
with 1.38 g (1.5 mmol) tris-(tetra-n-butylammonium)thiodiphosphate in CH3CN (2 mL)  at 0 °C. 
The reaction mixture was allowed to warm to room temperature over 8 h, then solvent was 
removed under reduced pressure. The residue was dissolved in 1 mL of cation-exchange buffer 
(49:1 (v/v) 25mM NH4HCO3/2-propanol) and passed over 90 equiv of Dowex AG50W-X8 (100-
200 mesh, ammonium form) cation-exchange resin, pre-equilibrated with two column volumes 
of the same buffer. The product was eluted with two column volumes of the same buffer, flash 
frozen, and lyophilized. The resulting powder was dissolved in 1 mL of 50 mM NH4HCO3, 2-
propanol/CH3CN (1: 1 (v/v), 2 mL) added, and the mixture mixed on a vortex mixer, then 
centrifuged for 5 min at 2000 rpm. The supernatant was decanted. This procedure was repeated 
three times and the supernatants were combined. After solvent removal and lyophilization, 
followed by flash chromatography on cellulose column (2:1:1 (v/v/v) 2-propanol/CH3CN/50 mM 
NH4HCO3), a white solid 24 mg (yield 15 %) was obtained. 1H NMR (400 MHz, D2O): δ, 4.05-
4.03 (m, 2H), 3.44-3.40 (m, 2H); 13C NMR (125.7 MHz, D2O): δ, 82.46, 81.03, 49.89, 18.43; 31P 
NMR (161.9 MHz, D2O): δ, 7.83 (d, J = 26.4 Hz), - 9.50 (d, J = 26.4 Hz); High-resolution mass 




2.6 Scheme and Figures 
 
Scheme 2.1. IspH catalysis. The reaction involves the 2H+/2e- reductive dehydroxylation of (E)-
1-hydroxy-2-methylbut-2-enyl-4-diphosphate (3) to dimethylallyl diphosphate (1) and 









Figure 2.1. Sequence similarity network of the IspH family proteins with 15,660 members 
constructed at an expectation-value (e-value) of 10-120. A single node represents sequences with 
at least 90% similarity. Major clusters of interest include: (a) Gammaproteobacteria (dark cyan, 
upper left) and Betaproteobacteria (blue, lower right); (b) Alphaproteobacteria (cyan); (c) 
Firmicutes (purple); (d) Firmicutes (with very long sequences, red); (e) Bacteroidetes (yellow); 
(f) Actinobacteria (orange); (g) Cyanobacteria and plants (green); (h) Apicomplexa (pink, genus 
Plasmodium, the malaria parasites) and (i) Desulfobacterales (brown, an order of 
Deltaproteobacteria). (j) the architectures of IspH-RPS1 with 4 (top) and 6 (bottom) S1 repeats; 




Figure 2.2. Sequence similarity network of IspH-RPS1 cluster, expectation-value (e-value) of 
10-160. Blue: Clostridia. Orange: Negativicutes. Green: Thermotogae. Red: Fusobacteria. Circle: 




Figure 2.3. Other IspH fusion proteins found from the sequence similarity network. (a) CMP-
IspH-RPS1 from Candidatus Arthromitus SFB-X (X=1, 2, 3, 4, 5, mouse-NL, and rat). (b) IspH-
helicase, from Bacteroidales bacterium CF. (c) FBP-IspH from Chromera velia. (d) UDP-IspH 
from Frankia sp. (QA3., EUN1f., and strain EAN1pec). (e) IspH with an N-terminal conserved 











Figure 2.4. The UbiA superfamily. The UbiA superfamily has a diverse range of substrates for 
prenylation and the substrates/products in several cases are not known. The sub-groups of UbiA 
and their substrates are listed. Atoms in red indicate the sites of prenylation. The UbiA in the 






Figure 2.5. IspH structures and IspH-fusion protein structure predictions. (a) X-ray structure of 
E. coli IspH (PDB ID code: 3KE8). (b) X-ray structure of P. falciparum IspH (PDB code: 
4N7B). (c) Phyre2 structure prediction of CthIspH-RPS1. The IspH domains are in orange while 
the 4 S1 repeats are colored green, purple, blue, or cyan. (d) Phyre2 stucture prediction of 
Desulfobacula toluolica IspH-UbiA. Orange: IspH domain. Blue: UbiA domain. Green: X-ray 
structure of Aeropyrum pernix UbiA (PDB ID code: 4OD5) Yellow spheres: conserved Cys in 




Figure 2.6. Characterization of CthIspH-RPS1 and its truncation mutants. (a) MALDI-TOF 
spectrum of purified CthIspH. M1: CthIspH-RPS1; M2: EcRho, see Text for more details. (b) 
UV-Vis spectrum of CthIspH-RPS1 after iron-sulfur cluster reconstitution (black) and after 
dithionite reduction (red). (c) Michaelis-Menten kinetics of CthIspH-RPS1. (d) Cartoon of the 
truncation proteins. D0: no S1 repeat, D1: one S1 repeat, D2: two S1 repeats, D3: three S1 
repeats. WT has the four S1 repeats. (e) Relative activities of truncation mutants compared to 
wild-type protein. Error bars are from n=3 replicates. (f) EPR of reduced CthIspH-RPS1, its 
truncation mutants, and E. coli IspH. (g) EPR of CthIspH-RPS1_1-171, reduced protein, with 
substrate HMBPP (1) and several ligands. The small peak at g=2.0 in the oxidized protein 






Figure 2.7. LC-MS of CthIspH-RPS1 catalyzed reaction confirmed the production of 




















Figure 2.8. Inhibition of CthIspH-RPS1. (a) Compounds tested in the CthIspH-RPS1 inhibition 
assays and their IC50 values against CthIspH-RPS1 (top) and AaIspH (bottom). (b) Dose-
response inhibition curves of three acetylene inhibitors. (c) 9 GHz EPR spectra of CthIspH-RPS1 










Figure 2.9. (a) E. coli Rho transcription termination factor MS fingerprint. Covered peptide 
fragments are shown in red. (b) SDS-PAGE gel showing that EcRho can be dissociated from 

















Figure 2.10. Possible IspH-RPS1/RelA/Rho ribosome interactions. Upon binding to the 
ribosome through the RPS1 domain, IspH could interact with RelA and affect its activity. The 
ppGpp released modulates a series of cell activities, for example inhibiting RNA polymerase 
(RNAP). The transcription termination factor Rho could also be affected upon interacting with 
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3.2 Introduction 
The enzymes IspG ((E)-1-hydroxy-2-methyl-but-2-enyl 4-diphosphate synthase, also 
known as GcpE) and IspH ((E)-1-hydroxy-2-methyl-but-2-enyl 4-diphosphate reductase, also 
known as LytB) are the last two enzymes of the 2-C-methyl-D-erythritol 4-phosphate (MEP) 
pathway of isoprenoid biosynthesis in many bacteria, as well as in some protozoa, and in plants7. 
They are both 4Fe-4S cluster-containing proteins that are involved in 2H+/2e reductions: IspG 
converts 2-C-methyl-D-erythritol-2,4-cyclo-diphosphate (MEcPP, 1, Scheme 3.1) to (E)-1-
49 
hydroxy-2-methyl-but-2-enyl 4-diphosphate (HMBPP; 2), and IspH converts 2 to dimethylallyl 
diphosphate (3) and isopentenyl diphosphate (4), the building blocks of isoprenoid biosynthesis. 
Both enzymes are not produced by humans (who use the mevalonate pathway for isoprenoid 
biosynthesis), but are essential in plants and in many bacteria and protozoa, so IspG and IspH are 
of interest as potential herbicide or drug targets. In earlier work8 we reported the first structure 
(PDB ID 3DNF) of an IspH, from Aquifex aeolicus, finding that one Fe atom in the cluster was 
lost during crystallization, and similar results (PDB ID 3F7T) were reported for IspH from E. 
coli55. However, using computational modeling to add back the unique 4th Fe, together with 
computational docking of the HMBPP substrate 1, we were able to produce7-8 ligand-bound 
structures that were very similar to later 4Fe-4S IspH/1 X-ray structures9, 37, and these structures 
have led to detailed mechanism of action models10, 56-57 for IspH catalysis. In other early work we 
discovered, based on previous reports that alkynes could bind to and be reduced by 4Fe-4S 
clusters58-59, that alkyne diphosphates such as 5 (propargyl diphosphate, PPP) were low µM 
inhibitors of IspH (as well as IspG, which also contains a 4Fe-4S cubane-like structure)7. Plus, 
the 1-amino (6) and 1-thio (7) analogs of HMBPP have been found to inhibit IspH with Ki ~20-
50 nM60-61, and we62 and others (PDB ID codes: 3ZGL, 3ZGN) have reported their X-ray 
structures which are basically the same as found with the HMBPP substrate, with N,S binding to 
the unique, 4th Fe. We also reported63 several other IspH-ligand complex structures with, in each 
case, a single O-containing ligand (alcoholate or enolate) bound to the unique, 4th Fe atom with 
Fe-O bond lengths of ~2 Å. What has been (and still is) missing is the X-ray structure of a 
“ligand free” IspH-either reduced ([Fe4S4]+) or oxidized ([Fe4S4]2+), the problem being that it has 
not been possible to crystallize the 4-Fe containing protein. However, the results of 57Fe 
Mössbauer spectroscopy11 indicated the presence of a 5 or 6-coordinate 4th iron in “ligand-free” 
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oxidized IspH, with three cluster S and most likely three additional N/O ligands bound to the 4th 
Fe. More recently, Faus et al.13 reported a NRVS (nuclear resonant vibrational spectroscopy) 
investigation of oxidized IspH and suggested that the three non-cluster ligands were H2O 
molecules (or presumably OH-, or a mixture of both). This structure is surprisingly labile, 
leading under crystallization conditions to loss of the 4th Fe. “Ligand-free” IspH is also very 
sensitive to O2 while HMBPP, PPP, as well as an enolate-liganded species are much less 
sensitive to cluster degradation by O264, suggesting that the presence of relatively bulky ligand 
side-chains might block the H2O/O2 binding that leads to lability. For example, in the PPP (5) 
structure (crystallized from oxidized IspH), there is a single H2O (or OH-) bound to the 4th Fe63 
while the acetylene group is ~3.6 Å from the Fe, acting perhaps as a barrier to water and oxygen 
ligands.             
In our EPR work on reduced IspH-5, we concluded (based in part on early observations 
of Fe4S4–acetylene interactions) that there could be p-bonding with the 4th Fe in the reduced 
cluster, but with oxidized IspH, S = 0, so the system is not accessible via EPR and it is not clear 
if there is any alkyne interaction with the cluster. We thus used NRVS to investigate the IspH-5 
system. In addition, we used HYSCORE (hyperfine sublevel correlation spectroscopy) to 
investigate how another small ligand, CN-, might bind to reduced IspH, of interest since CN- can 
be involved in p-back-bonding with d-orbitals. The results of these experiments together with an 
examination of numerous IspH and IspG structures suggested the importance of h1 s-bonding of 
ligands to the 4th Fe, together with the presence of a bulky side-chain, for IspH inhibition, so we 
then used in silico screening of possible inhibitors, finding interesting new drug-like leads that, 
we propose, bind in this manner. 
3.3 Results and Discussion 
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In the following we first investigated the interactions of IspH with the alkyne diphosphate 
5, as well as with a small molecule ligand, CN-, to see if there were any interactions of the alkyne 
with the cluster, and whether the anionic species CN- bound since in principle, both might be 
involved in metal-ligand π-bonding/back-bonding. Then, using information from these and other 
related studies, we used in silico screening to try and find new, drug-like inhibitor leads. 
3.3.1 NRVS Spectroscopy of the IspH-5 Complex.  
NRVS provides 57Fe-specific information on the partial vibrational density of states 
(PVDOS) for Fe-X vibrational modes in a molecule65. For systems containing 4Fe-4S cubane-
like clusters, such as IspH, there are typically four main NRVS features, as shown schematically 
in Figure 3.1a65-68: cluster torsional modes occur at <100 cm-1; d (S-Fe-X) bending modes at 
~150 cm-1; n (Fe-S) (cluster) stretching modes at ~280 cm-1 and n (Fe-Ster) (terminal) stretching 
modes in the ~320-370 cm-1 range. Although there are of course additional mixed modes, these 
NRVS spectral features are present in most if not all species containing 4Fe-4S as well as 4Fe-3S 
clusters.65-68 For example, the NRVS spectrum of oxidized Pyrococcus furiosus ferredoxin 
containing a D14C mutation (which therefore has 4 Cys ligands;  Figure 3.1b, black line)67, is 
very similar to that seen with the model compound [Fe4S4Cl4](Ph4P)2, which contains a 
[Fe4S4Cl4]2- cluster in which the four terminal ligands are Cl (Figure 3.1b, grey line)[20]. 
Basically the same features are also seen in oxidized IspH with HMBPP (2), the amino-analog 
(6) or the thiol analog (7) as ligands 13, in which O, N or S are directly bonded to the 4th Fe. In 
sharp contrast, these features are all less obvious (or absent) in the NRVS spectrum of IspH in 
the absence of 2, 6 or 713. In the presence of NO, the 4Fe-4S cluster in P. furiosus D14C 
ferredoxin69  is converted to Roussin's black salt, [Fe4S3(NO)7]-  and the same set of peaks (at 
~150, 280 and 370 cm-1) as seen in the 4-Cys liganded protein are present. However, there are in 
C) 
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addition strong peaks at ~540, 610 cm-1, Figure 3.1b (red line), suggesting a contribution from 
Fe-N-O and/or N-Fe-N vibrational modes, due in part to metal-ligand pi-bonding. We thus 
investigated the NRVS spectra of the IspH-5 complex to see whether there might be any 
evidence for interaction between the alkyne group and the oxidized 4Fe-4S cluster (Fe-C 
bonding) that we previously proposed to be important in the reduced protein. 
     We show in Figure 3.1c the NRVS spectrum of EcIspH in the oxidized state ([Fe4S4]2+) 
bound to 5 (red line). The spectrum is very similar to that seen with HMBPP (2) as well as the 
amino 6 and thiol 7 analogs of HMBPP, bound to IspH,13 and the [Fe4S4Cl4]2- model 
compound13, consistent with each Fe being bound to 3 cluster sulfurs and a single 4th atom. We 
also found no spectral shifts when a uniformly 13C-labeled analog of PPP (5) was bound to the 
protein (blue line, Figure 3.1c). These results are consistent with the presence of a single water 
molecule 63 binding to the 4th Fe—the tetrahedral geometry seen in the other IspH structures with 
2, 6 and 7 13—with no significant bonding between the alkyne group and the cluster.  A 
compilation of the NRVS spectra of all of the variously ligated protein and model compound 
4Fe-4S cluster-containing systems discussed above, highlighting their similarities, is shown in 
Figure 3.2. The spectra with 5 are also dissimilar to that observed with IspH containing 3 H2O 
molecules bound to the 4th Fe, again consistent with the lack of multiple (alkyne, water) 
interactions with the 4th Fe.  
We next sought to see how other small molecules/ions might bind to the 4Fe-4S cluster. 
Attempts to bind CO were unsuccessful, as determined by UV-VIS and EPR spectroscopy. 
However, in previous work70 we showed that CN- bound to reduced IspH, yielding an EPR 
spectrum characterized by g-values of 2.08, 1.94 and 1.93 (with a small shoulder at g = 2.0570), 
but the number of ligands as well as the binding mode were unknown. We thus next collected 
53 
HYSCORE spectra using [13C15N]- bound to E. coli IspH. As can be seen in Figure 3.3a, there 
are clearly HYSCORE features that are consistent with binding of a single CN- to the unique, 4th 
Fe in the cluster. Using the EasySpin program71 we simulated hyperfine coupling tensors of 
A(13C) = [-3.9, -3.8, 0.1] MHz, Figure 3.3b, and A(15N) = [1.1, 1.1, 2.3] MHz, Figure 3.3c. 
Interestingly, the g-values observed70 in the EPR spectrum of IspH•CN (g=2.08, 1.94, 1.93) are 
virtually identical to those found (g = 2.09, 1.94, 1.93) for CN- bound to Shewanella oneidensis 
HydG (minus the “dangler Fe”)72 involved in formation of the [Fe(CO)2CN] synthon in 
hydrogenase function. Moreover, the HYSCORE spectrum of [13CN]-SoHydG has a 13C 
isotropic hyperfine coupling Aiso = -2.7 MHz, similar to the Aiso = -2.9 MHz in PfFd with bound 
13CN73 and the Aiso ~ 2.5 MHz we find here. Plus, the 15N HYSCORE result for [13C15N]- bound 
to SoHydG 72 is extremely similar to that we observe with IspH. So, IspH, SoHydG (the 4Fe-4S 
cluster) as well as the (wild type) ferredoxin all appear to bind CN- to the 4th Fe, forming a 
tetrahedral species. It should be noted, however, that CN- is actually a very poor IspH inhibitor 
(IC50>1 mM) and, as noted by Suess et al.72, CN- binds only weakly to other biological73 as well 
as synthetic74 4Fe-4S clusters, and cysteine displaces CN- from HydG72.  
3.3.2 Ligand Binding to IspH and IspG: Clues for Inhibitor Discovery?  
When taken together, the results shown above together with other reported work7, show 
that there are several ways that ligands can bind to IspH, and suggest a potential route to finding 
new inhibitors. First, most ligands bind with h1 coordination with O, N and S binding via s-
interactions with the 4th Fe. Second, potential p-bonding species (CN-, CO, propargyl alcohol) do 
not bind strongly. Third, while h2 as well as h3 coordination is possible7, these cases are rare. 
Fourth, when alkyne diphosphates bind to oxidized IspH, the main cluster interaction is with a 
4th H2O (or OH-), the alkyne fragment blocking addition of further H2O molecules. Fifth, the 
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diphosphate moiety must contribute in a major way to IspH inhibition, because propargyl alcohol 
itself is a very weak inhibitor (Ki>10 mM). Sixth, these general patterns of ligand binding are 
very similar in IspH and in IspG. This is shown in Figure 3.4a in which we compare PPP (5) 
binding to IspH and IspG. In both cases, there is a 4th H2O bound to the unique 4th Fe (dFe-O = 1.9 
Å), while the alkyne is more distant (d ~3.6 Å). The IspH•5 structure is very similar to the 
structures found with the amino (6) and thiol (7) HMBPP analogs, the IspH•5 water being in the 
same position as the 6, 7 NH2 and SH groups, and the diphosphate groups overlap, Figure 3.4b. 
The IspH•5 water also co-locates with the ligand-bound oxygen in the IspG-MEcPP (1) 1st 
reaction intermediate75, Figure 3.4c, and the IspG•5 bound water is in the same position as a 
carboxylate oxygen in E307, in IspG (Figure 3.4d). So, in the vast majority of cases the 4th Fe 
has a tetrahedral coordination geometry with O, N or S binding to Fe. Unfortunately, these potent 
diphosphate-containing inhibitors are not active in cells, presumably because the diphosphate 
groups are very highly charged, reducing cell penetration. These observations led us to try and 
find more lipophilic, drug-like species that might bind to Fe, while also occupying the relatively 
large substrate-binding pocket.  
We thus next used an in silico approach to screen a library of drug-like compounds from 
the ZINC and NCI libraries against both Aquifex aeolicus IspH (PDB ID 3DNF) and E. coli IspH 
(PDB ID 3F7T). In both cases, the 4th Fe was reconstituted computationally as described 
previously8, and we used Glide docking76, again as described previously77. Using this approach 
we obtained and tested 15 potential hits (Figure 3.5) that were commercially available, for IspH 
inhibition. 14 out of the 15 compounds were inactive (IC50 > 1 mM), but 8 was active. We then 
obtained and tested 11 commercially available analogs of 8 (Figure 3.6) and tested them against 
E. coli IspH and Pseudomonas aeruginosa IspH, both organisms (unlike A. aeolicus) being 
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important pathogens. The most active compounds were 8 and 9 with 8 having a Ki = 500 nM 
against P. aeruginosa IspH, Figure 3.7a, and the benzyl analog 9 having a Ki = 3 µM, against E. 
coli IspH, Figure 3.7b. AaIspH was also inhibited by 9 with a Ki=700 nM. These compounds are 
barbituric acid analogs that have some structural similarity to anti-infectives developed by 
Pharmacia78, and are predicted to bind to the 4th Fe of the 4Fe-4S cluster. A view of the 
AaIspH•9 complex (obtained by docking) from the electron-transfer side of the protein is shown 
in Figure 3.7c; a bottom-view (substrate side) in Figure 3.7d, and a side-view in Figure 3.7e. A 
close up view of the ligand interacting with the 4th Fe in the cluster (dFe-N = 2.6 Å; dFe-O = 2.7 Å) 
is shown in Figure 3.7f. The ligand can clearly occupy the large substrate-binding site seen in the 
early X-ray structures, with the enolate form of the barbiturate reacting with the Fe, similar to the 
binding of related barbiturate enolates to Zn2+ in other metalloproteins 79-80. 
Interestingly, we were unable to obtain EPR spectra of 9 bound to IspH (from the 
pathogen Pseudomonas aeruginosa), ligand addition resulting in loss of signal intensity, Figure 
3.7g, due perhaps to a shift in redox potential on ligand binding, or a change in relaxation 
behavior but in either case, 8, 9 appear to represent interesting new IspH inhibitor leads for 
further development since they are far more lipophilic than the diphosphates, they do not violate 
Lipinski's rules81 and they are not PAINS compounds82. 
3.4 Conclusions  
The results we have shown above are of interest for a number of reasons. First, we find 
that NRVS spectra of the alkyne diphosphate inhibitor 5 bound to oxidized IspH are very similar 
to those found for binding of HMBPP 2, as well as the amino and thiol analogs of HMBPP, 6 
and 7. There is no evidence for any alkyne-cluster interaction. Second, we show (using 
HYSCORE) that CN- binds to IspH (but is a very weak inhibitor), and that the EPR/HYSCORE 
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spectra of the CN- bound protein are very similar to those found with CN- binding to SoHydG 
and P. furiosus ferredoxin, consistent with binding of a single cyanide in all three cases. Third, 
when compared with all known IspH and IspG structures, it is clear that in most cases, O, N and 
S-bonding ligands bind to the unique 4th Fe in the cluster forming tetrahedral geometries. Fourth, 
based on the results noted above, we sought to find novel IspH inhibitors that might bind to Fe in 
the active site and be more drug-like than the diphosphate inhibitors. Using in silico screening 
we found that the barbiturate analogs 8, 9 had Ki ~ 0.5-3 µM, binding we propose, via the 
barbiturate enolate moiety to the 4th Fe, the hydrophobic domains occupying the substrate-
binding site.  
3.5 Experimental Section 
3.5.1 Chemical Synthesis: General Methods 
8 and its analogs were purchased from Vitas-M Laboratory (Hong Kong) and used 
without further purification. Compounds were analyzed by LC/MS and were >97% pure. Other 
compounds were from Aldrich, Asinex, Enamine, NCI/Developmental Therapeutics Program 
Open Chemical Repository (dtp.cancer.gov/), or TimTec. All chemicals for the re-synthesis of 9 
were purchased from Sigma-Aldrich. 1H NMR spectra were obtained on Varian Unity 
spectrometers at 400 and 500 MHz. High resolution MS and elemental analyses were carried out 
in the University of Illinois Mass Spectrometry and Microanalytical Laboratories. 
3.5.2 8-amino-3-benzyl-2,3,4,4a-tetrahydro-1H,2'H,6H-spiro[pyrazino[1,2-a]quinoline-5,5'-
pyrimidine]-2',4',6'(1'H,3'H)-trione (9).  
The synthesis of 9 was based on the synthesis of a morpholine analog83, and is illustrated 
in Scheme 3.2. 1-benzylpiperazine (9a). Piperazine (59 mmol, 5.09 g) was dissolved in 26 mL of 
THF by heating. Benzyl bromide (8.4 mmol, 1mL) was added dropwise to a refluxing solution of 
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piperazine in THF. After stirring overnight at reflux, the reaction was cooled, and THF removed 
by evaporation. The resulting residue was washed with aq. K2CO3 (20 mL), extracted with 
EtOAc (10 mL x 3), washed with satd. NaCl (10 mL x 1), dried with Na2SO4, then evaporated to 
dryness under vacuum (9a, 1.29 g, 87%). 9a (207 mg, 1.174 mmol) was dissolved in 3 mL 
MeCN and 1 mL Et3N. Then, 2-fluoro-5-nitrobenzaldehyde (200 mg, 1.18 mmol) was added and 
the solution stirred at reflux overnight. The reaction mixture was then diluted with EtOAc (10 
mL) and washed with water (10 mL). The aqueous layer was extracted with EtOAc (10 mL x 2), 
dried with Na2SO4, then solvent removed under vacuum. The crude mixture was purified by 
column chromatography (2:1 Hex:EtOAc, 9b, 272 mg, 71% yield). 9b (192.77 mg, 0.592 mmol) 
was dissolved in 10 mL MeOH. To this solution, barbituric acid (79.76 mg, 0.623 mmol) was 
added and the mixture heated to reflux and stirred overnight. The crude reaction mixture was 
loaded onto a column and purified with 2:3 EtOAc:Tol (9c, 77.33 mg, 30%). 9c (30 mg, 0.069) 
was dissolved in 8 mL AcOH and Zn dust (52 mg, 0.795 mmol) added. The reaction mixture was 
stirred at room temperature for 2 hours and then quenched with K2CO3 (20 mL). Next, the 
mixture was diluted with EtOAc (20 mL) and washed with aq. K2CO3 (20 mL), satd. NaCl, dried 
with Na2SO4, then solvent was removed under vacuum. The crude mixture was purified by 
preparative TLC (100% EtOAc) to yield an orange powder 9 (3.92 mg, 9%). ESI-HRMS: Calc: 
406.1879, found: 406.1868 C22H24N5O3.  Compound purity determined by HPLC (Phenomenex 
C6-Phenyl 110A, 100x2 mm, 3µM, 250 nm, retention time = 1.5 min): 99.7%. 
3.5.3 Sample preparation. 
57Fe IspHs were prepared as described elsewhere.9. Compound 5 was described 
previously 70. For EPR spectroscopy, EcIspH and PaIspH in the oxidized state ([Fe4S4]2+) and in 
the presence of a 20-fold excess of 5 were concentrated to ~0.3 mM by using an Amicon Ultra 
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centrifugal device (EMD Millipore Corporation, Billerica, MA, USA),  then glycerol was added 
to 20% (v/v) as a glassing agent. NRVS EcIspH samples were loaded into a Lucite cuvette 
(internal dimensions = 10 x 2.5 x 1  mm), then frozen in liquid nitrogen.  
3.5.4 NRVS Measurements.  
NRVS samples (6 mM EcIspH) were attached to a cryogenic sample base connected to a 
liquid helium (LHe) cryostat maintained at 10K. Spectra were recorded using published 
procedures at 03-ID at the Advanced Photon Source (APS) 84. Photon flux was ~2.5 x 109 
photons/s in a 1.1 eV energy resolution. Delayed nuclear fluorescence Fe K fluorescence were 
recorded with a single 1 cm2 square avalanche photodiode. Total data aquisition time was 19 
hours. Data reduction was performed by using the PHOENIX software package85 where the 
observed raw NRVS spectra were calibrated (aligned) to the nuclear resonant peak, normalized 
to the I0, then summed and converted to the 57Fe partial vibrational density of states (PVDOS). 
The spectral conversion was optimized when the observed Stokes/anti-Stokes imbalance 
matched the imbalance calculated using the entered temperature as a variable. The real sample 
temperature obtained by using this procedure was ~60 K. 
3.5.5 CW-EPR/ENDOR/HYSCORE spectroscopy.  
All CW (continuous wave)-EPR experiments were performed on a Varian E-line 122 X-
band spectrometer with an Air Products helium cryostat. Typical data acquisition parameters 
were: microwave frequency = 9.05 GHz; field center = 3250 G; field sweep = 1000 G; 
modulation frequency = 100 kHz; modulation amplitude = 5 Gauss; time constant = 32 ms; 
temperature = 8 – 20 K. HYSCORE spectra were obtained on a Bruker ElexSys E-580-10 FT-
EPR EPR spectrometer equipped with an Oxford Instruments CF935 cryostat. HYSCORE used a 
four-pulse sequence π/2mw − τ − π/2mw − t1 − πmw − t2 − π/2mw − echo; π/2mw = 16 ns and πmw = 
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32 ns, 128 points for both t1 and t2, each using 24 ns steps. Time-domain data were baseline 
corrected using a 3rd order polynomial, then Hamming windowed, followed by zero-filling, 2D-
Fourier transformation, and symmetrization. Parameters were typically: microwave frequency = 
9.65 – 9.72 GHz, temperature = 8 – 15 K, microwave power attenuation = 6.5 – 9 dB. 
3.5.6 Spectral simulations.  
HYSCORE spectra were simulated by using the EasySpin program71. 
3.5.7 In silico screening. 
 In order to find new inhibitors, we carried out in silico screens of AaIspH and EcIspH 
















3.6 Schemes and Figures 
 
Scheme 3.1. Structures of IspG (GcpE) and IspH (LytB) substrates and reaction products, and 


















Figure 3.1.  NRVS spectra. (a) Cartoon representation of a NRVS spectrum of a 4Fe-4S cluster-
containing σ-bonding ligands (e.g. OR, NHR, SR, Cl) at a 4th, unique Fe-site. (b) Experimental 
spectra of oxidized P. furiosus D14C ferredoxin (PfFd; black), PfFd+NO (red) and 
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Figure 3.2.  IspH and model compound NRVS spectra comparisons. (a) Spectra from Figure 
3.1b. (b) Spectra from Figure 3.1c. (c)-(e) Spectra from Reference 16 in the Text. The frequency 
axes are all scaled to be the same and the green bands have been added to show that the 3 main 









Figure 3.3. HYSCORE spectra of IspH•CN. (a) Experimental HYSCORE spectrum of 
EcIspH•13C15N. Sample is reduced ([Fe4S4]+) with dithionite. (b) Simulation of 13C hyperfine 
coupling with A = [-3.9, -3.8, 0.1] MHz, Euler angle = [0, 40±5, 0]°. (c) Simulation of 15N 
hyperfine coupling with A = [1.1, 1.1, 2.3] MHz, Euler angle = [0, 30±10, 0]°. Euler angle 


















Figure 3.4. Comparisons between IspH/IspG structures with various ligands binding to the 
unique, 4th Fe site. (a) PPP (5) bound to EcIspH (red) and EcIspG (green) (PDB ID codes 3URK, 
4S3E). (b) Superposition of EcIspH PPP (5)/H2O (red) and thiolate (cyan, 7) X-ray structues 
(PDB ID codes 3URK, 4H4E). (c) Superposition of PPP (5)/H2O IspG (green) structures with 
PPP (5)/H2O-GcPE reaction intermediate structures (magenta) (PDB ID codes 4S3B, 4S3E). All 
structures contain a σ-bonding ligand (H2O, RNH2, RSH, enolate) at the unique, 4th Fe structure. 
Three water molecules binding to 4th Fe lead to low stability; a H2O and a “bulky” ligand (that 
prevents binding of additional water molecules) leads to more stable species. (d) Superposition 
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Figure 3.7. IspH inhibition by barbiturate analogs. (a),(b) Dose-response curves for EcIspH 
inhibition. (c) Computational docking structure of 9 binding to oxidized AaIspH. View from 
electron transfer side.  (d) View from substrate binding side. (e) Side view. (f) Proposed binding 
of the barbiturate enolate group in 9 to the unique, 4th Fe in the 4Fe-4S cluster in oxidized 
AaIspH. (g) 9 GHz EPR spectra of PaIspH. Oxidized protein (top, orange); dithionite reduce 
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CHAPTER 4: BISPHOSPHONATE-GENERATED ATP-ANALOGS INHIBIT 
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4.1 Notes and Acknowledgments 
We thank Dr. Jouko Vepsäläinen, Dr. Yoshimasa Tanaka, Dr. Eric Champagne, Dr. 
Javier Alguacil and Dr. Suzanne Peyrottes for providing ApppI samples; Dr. Yang Wang and Dr. 
Guodong Rao for helpful advice; Prof. Robert Gennis and Prof. Jefferson Chan for providing 
access to instrumentation, and Dr. Hong Chen for providing cells.  
This work was supported in part by the United States Public Health Service (National 
Institutes of Health Grants GM065307 and CA158191 to EO, and GM085774 to YZ), by a 
Harriet A. Harlin Professorship, by the University of Illinois Foundation/Oldfield Research Fund 
and by the Academy of Finland (Decision No. 292574 to PT). We thank Jouko Vepsäläinen, 
Yoshimasa Tanaka, Eric Champagne, Javier Alguacil and Suzanne Peyrottes for providing 
ApppI samples; Yang Wang and Guodong Rao for helpful advice; Robert Gennis and Jefferson 
Chan for providing access to instrumentation, and Hong Chen for providing cells.  
4.2 Introduction 
Bisphosphonates are a major class of drugs used to treat bone-related diseases.1 They are 
analogs of diphosphate, and first-generation “non-nitrogen” bisphosphonates (NNBPs) such as 
clodronate (1, Figure 4.1), etidronate (2) and tiludronate (3) were discovered in 19692 as an 
outgrowth of earlier work3 in which diphosphate was shown to affect hydroxyapatite 
formation/dissolution. NNBPs were initially thought to have a “physical” mechanism of action, 
by binding to the bone surface (Figure 4.2a). In 19924 it was then shown that NNBPs were 
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converted to ATP-analogs such as 4, 5,4(Figure 4.2b) and it was proposed that these ATP-
analogs might inhibit enzymes. Then, “nitrogen-containing" bisphosphonates (NBPs) such as 
zoledronate (6) were developed and in 19995,6 (Figure 4.2c), these were shown to target farnesyl 
diphosphate synthase (FPPS), which catalyzes the condensation of dimethylallyl diphosphate 
(DMAPP; 7) with isopentenyl diphosphate (IPP; 8) to form farnesyl diphosphate (FPP; 9), 
essential for protein prenylation/cell signaling. FPP is also converted by geranylgeranyl 
diphosphate synthase (GGPPS) to geranylgeranyl diphosphate (GGPP; 10), again used in protein 
prenylation. In 2002,7 4 was shown to inhibit the mitochondrial ADP/ATP translocase (ANT), 
providing a basis for the mechanism of action of the NNBPs (Figure 4.2d). And in 2009, it was 
shown that NBPs could generate other ATP-analogs: the isopentenyl ester of ATP, 11, as well as 
the dimethylallyl ester, 12. These form because FPPS inhibition results in large increases in the 
levels of the FPPS substrates 7,8 which are converted to the ATP-esters 11 and 12 (Figure 4.2e). 
As with the clodronate analog 4, compound 11 was shown to inhibit the ANT in mitochondria, 
leading to cell death.8  
     In addition to their role in treating bone-resorption diseases, bisphosphonates kill tumor cells9 
and are being tested in Europe as adjuvant cancer therapeutics.10 However, their mechanisms of 
action are still not clear since in recent work11,12 it was proposed that NBPs directly inhibit the 
epidermal growth factor receptor (EGFR), Figure 4.2f. There was, however,  a puzzling “dose 
discrepancy" between the effects of bisphosphonates in cell-free systems (IC50 ~500 µM in 
EGFR inhibition assays) versus cell-based assays (EC50 ~50 µM), in tumor cell killing,11 12 and 
the 500 µM value for EGFR inhibition is ≈5-6 orders of magnitude larger than that found with 
conventional EGFR inhibitors. We thus sought to deduce models for bisphosphonate activity that 
might help explain these previous observations. We tested three hypotheses: First, NBPs do not 
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directly inhibit the EGFR. Rather, the ATP analogs 11 and 12 are the kinase inhibitors, because 
these compounds have structural similarity to ATP. Second, with NNBPs such as clodronate, we 
hypothesized that ATP-analogs such as AppCCl2p (4; adenosine 5’-(beta, gamma-
dichloromethylene) diphosphate) also inhibit kinases. Third, we hypothesized that if species such 
as AppCCl2p inhibited kinases, then lipophilic "pre-prodrug" forms of the NNBPs13 might act by 
inhibiting cell signaling pathways. We tested these hypotheses using results for a broad range of 
NBPs and NNBPs,  AppXp ATP-analogs (where X is a variable group that bridges Pb and Pg) 
and AppXp pre-prodrugs in, as appropriate, kinome screens with 369 kinases, 47 individual 
kinase dose response assays, cell growth inhibition assays using 6 cell lines, Western blots, 
mitochondrial respiration assays, FPPS and GGPPS inhibition, ApppI formation assays, as well 
as geranylgeraniol (GGOH) “prenylation rescue” assays. 
4.3 Results and Discussion 
4.3.1 Bisphosphonates are Not Potent EGFR Inhibitors. 
We first investigated the effects of 11 bisphosphonates (8 NBPs and 3 NNBPs) on EGFR 
inhibition using a wild type EGFR kinase-domain assay, with poly[Glu:Tyr](4:1) and [g-33P]-
ATP as substrates. Dose-response curves are shown in Figure 4.3 and numerical values are 
summarized in Table 4.1. The IC50 values were many orders of magnitude higher than we find 
with the known EGFR inhibitors staurosporine (IC50=26± 8 nM; n=6) or erlotinib (IC50~380 ± 
250 pM; n=2), ranging from ~30-40 µM (minodronate 13, tiludronate 3) to ~70-100 µM 
(zoledronate 6, risedronate 14 and a lipophilic bisphosphonate, 15,14 to >100 µM for alendronate, 
N-(2-(3 picolyl)aminomethylene bisphosphonate, ibandronate, pamidronate, etidronate and 
clodronate, Table 4.1, showing that inhibition of the EGFR by many bisphosphonates is very 
weak. In contrast, we found that the ApppI that accumulates in cells on FPPS inhibition inhibited 
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EGFR kinase activity with an IC50 of 9.2 ± 4 µM (n=6). Representative dose-response curves are 
shown in Figure 4.3. So, ApppI is a more potent EGFR inhibitor than any of the bisphosphonates 
tested, or indeed the ATP analog AMP•PNP, which has an IC50 of 36 µM in this assay. We also 
prepared and tested the dimethylallyl ester of ATP, ApppD (12)15 finding an IC50~14 µM (Figure 
4.3).  
     ApppI has been reported to accumulate in some cells to >100 µM levels, on bisphosphonate 
treatment8. However, given typical ATP concentrations in cells (~1-5 mM) and known KM [ATP] 
values (~5 µM16), it seems that EGFR inhibition by 11 or 12 will not be a major target for cell 
growth inhibition. In contrast, we found much more potent EGFR inhibition with AppCCl2p 
(IC50=640±120 nM), Figure 4.3, of interest since AppCCl2p levels in some cells can reach mM 
levels.8, 17 We thus find that bisphosphonates do not directly inhibit the EGFR in the same assays 
in which we obtain potent, low nM inhibition by the known kinase inhibitors, staurosporine and 
erlotinib. But the results do suggest the possibility that some ATP-analogs might potently inhibit 
this or other kinases—indicating the desirability of a large kinome screen.       
4.3.2 Kinome-screening Results for AppCCl2p and ApppI.  
To see whether any kinases were potently inhibited by AppCCl2p or ApppI, we carried 
out screens of 369 kinases using the HotSpotSM assay (Reaction Biology Corporation; 20 mM 
Hepes, pH 7.5, 10 mM MgCl2, 1 mM EGTA, 0.02% Brij-35, 1 µM ATP, single dose duplicate 
mode at 1 µM inhibitor) using both compounds. Results (computed IC50 values) are shown in 
Table 4.2 for the top 20 hits. In order to obtain more accurate results, we then carried out a series 
of 10-dose, dose-response assays for ApppI (8 kinases) and AppCCl2p (17 kinases). For the 17 
kinases where we obtained both dose-response as well as kinome screen results we found a 
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Pearson R-value correlation coefficient R=0.96 between the IC50 values for the two data sets 
(Figure 4.4).   
What the results in Tables 4.2 and 4.4 show is that there is potent (~10s nM) inhibition of 
several kinases (e.g. PDGFRa, JAK2, JAK3, FGFR2) by AppCCl2p, plus, many other kinases 
are inhibited at higher concentrations. Moreover, for JAK3 we determined Ki values at 1 µM and 
200 µM ATP levels and using reported KM ATP values18 we find Ki ~ 4-11 nM. However, the 
inhibitory effects of ApppI and ApppD are very much weaker. These results	have several 
implications. First, since AppCCl2p levels in clodronate-treated macrophages can reach mM 
levels17  and ApppI can reach ~130 µM8 (and ApppD is ~2x higher), numerous kinases will be 
inhibited although the effects will be much more pronounced with clodronate/AppCCl2p because 
the IC50 values there are ≈2-3 orders of magnitude smaller than with ApppI/ApppD.  Second, it 
has recently been shown19 in mice breast cancer models (as well as in one patient) that 
bisphosphonates bind to granular micro-calcifications that are then engulfed by tumor-associated 
macrophages (TAMs). This is expected to lead to high AppCCl2p levels in TAMs and as noted 
by Junankar et al.,19 TAMs are powerful promoters of tumor growth and metastasis,20 and 
extensive macrophage infiltration in many tumor types is associated with poor patient 
prognosis".21 It thus appears that some of the extra-skeletal effects of bisphosphonate therapy 
especially with breast cancer patients could arise from kinase inhibition in TAMs. In mice 
treated with NBPs, ApppI levels in osteoclasts reach ~20 µM,22 so direct kinase inhibition is 
unlikely to be a major contributor to activity. Third, clodronate and AppCCl2p levels in 
osteoclasts (from clodronate-treated mice) are expected to be similar to or greater than 
ApppI/ApppD levels, based on cell-based observations that clodronate and AppCCl2p 
concentrations in several clodronate-treated cell lines are ~3-5x higher than are zoledronate and 
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ApppI levels in zoledronate-treated cells.7, 9b, 22 As a result, many kinases in osteoclasts will be 
inhibited by clodronate/AppCCl2p. Fourth, clodronate levels in tissues in patients on systemic 
clodronate therapy are expected to be low because bisphosphonates bind avidly to bone mineral 
but intriguingly, there are several reports of the anti-	inflammatory effects of NNBPs23 so our 
finding that JAK 1/3 and Tyk2 are some of the kinases that are inhibited by AppCCl2p is of 
interest since the anti-inflammatory drug Xeljanz® functions by inhibiting JAK 1/3,24 and we 
find a 5 nM IC50 for JAK3 inhibition (and as discussed below, STAT3 involvement in activity 
with an AppXp analog). Fifth, we see that FGFR2 (the fibroblast growth factor 2 receptor) is 
inhibited by AppCCl2p (IC50 ~22 nM) and in earlier work25 it was shown that clodronate reduced 
FGF2-driven cell growth in HUVECs (human umbilical vein endothelial cells), but there was no 
effect in the absence of FGF2. In that work it was proposed that clodronate bound directly to 
FGF2, inhibiting its activity, but here, we now have evidence for low nM FGFR2 inhibition by 
AppCCl2p, suggesting a direct effect of the clodronate metabolite on FGFR2 cell signaling. 
Overall then, the kinase inhibition results reveal that there are multiple kinases that are quite 
potently inhibited (IC50 ~ 10s nM) by AppCCl2p, offering new insights into the mechanisms of 
action of the NNBPs.  
4.3.3 AppCCl2p and ApppI Target Different Kinase Classes.  
When all of the kinase inhibition results are examined it is apparent that there are four 
trends that relate to tyrosine versus serine/threonine kinase inhibition by AppCCl2p and ApppI, 
and kinase inhibition in general. First, the targets for AppCCl2p and ApppI are different. For the 
20 most potent “hits” in the kinome screens, AppCCl2p targets ~78% tyrosine kinases, 
highlighted in pink in Table 4.2, but only 22% of the top 20 are serine/threonine kinases, 
highlighted in cyan in Table 4.2. Second, only ~14% of the top 20 hits in the ApppI kinome 
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screen are tyrosine kinases but ~86% of the top 20 are serine/threonine kinases, Table 4.2. Third, 
the activities of AppCCl2p and ApppI when mapped onto kinome dendrograms (using the 
Kinmap program26) (Figure 4.5) clearly show that the vast majority of AppCCl2p targets are in 
the TK (tyrosine kinase) group, while ApppI inhibition is much more widespread and as noted, 
favors Ser/Thr kinases. Fourth, AppCCl2p is a much more potent kinase inhibitor than is ApppI 
(or ApppD). What, then, might be the molecular basis for the differential effects (on both activity 
and selectivity) of AppCCl2p and ApppI?  
4.3.4 A Molecular Basis for AppCCl2p Activity and Selectivity.  
The more potent and selective activity of AppCCl2p for Tyr versus Ser/Thr kinases could 
be due to stronger binding to Tyr kinases in general, model A, or to stronger binding to Tyr 
versus Ser/Thr OH groups in substrates, model B. The latter model is attractive since the 
phosphonate group in AppCCl2p would be expected to form a much stronger hydrogen bond 
with the aromatic Tyr than with the aliphatic Ser/Thr. This is because, as shown in Figure 4.6a, 
there can be strong hydrogen bonding (or tautomerism) between phosphonate/phenol and 
phosphonic acid/phenolate species that cannot occur with Ser/Thr due to the very high pKa 
values (~16) of aliphatic alcohols. These sorts of hydrogen bonds are well known in e.g. 
salicylates in which the carboxylate interacts with a phenolic OH.27  
We thus next used a LanthaScreen Eu kinase binding assay with activated JAK3 to 
determine (in the absence of substrate) the Ki for AppCCl2p binding. We found Ki=73 nM 
(Figure 4.7) which is much higher than the Ki ~4-11 nM found in the activity assays (at 1 and 
200 µM ATP). This means that the presence of a substrate Tyr is required for high affinity 
binding, supporting model B. Then, to test if phosphonate-tyrosine hydrogen bond interactions 
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are indeed  significantly different to phosphonate-serine/threonine interactions, we used density 
functional theory (DFT) and Atoms-in-Molecules (AIM) theory.28  
     AIM theory is a quantum chemical method that we and others have used to investigate 
the details of hydrogen bond interactions.29 According to AIM theory, every chemical bond has a 
bond critical point (BCP) at which the first derivative of the charge density, r (r), is zero. The 
r(r) topology is described by a real, symmetric, second-rank Hessian-of-r(r) tensor, and the 
tensor trace is related to the bond interaction energy by a local expression of the virial theorem: 
 
Tr(Hessian) = ∇2r(r) = [2G(r) + V(r)] (4m/ ħ2) (1) 
 
where ∇2r(r) is the Laplacian of (r), and G(r) and V(r) are electronic kinetic and electronic 
potential energy densities, respectively. Negative and positive ∇2r(r) values are associated with 
shared-electron (covalent) interactions and closed-shell (electrostatic) interactions, respectively. 
In the latter case, one can further evaluate the total energy density, H(r), at the bond critical 
point: 
 
H(r) = G(r) + V(r)    (2) 
 
A negative H(r) is termed partial covalence, while a positive H(r) indicates a purely closed-shell, 
electrostatic interaction30. We first used the models shown in Figure 4.6b to examine the 
differences in the interactions between a bisphosphonate (modeled here as Me(HPO3)-) and Tyr 
(modeled as PhOH), versus with Ser/Thr (modeled as MeOH). The optimized geometries for 
PhOH·Me(HPO3) and MeOH·Me(HPO3)- are quite similar (Figure 4.6b and Table 4.3.). As 
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shown in Table 4.3, the hydrogen bond in the Tyr (phenol) model system is clearly stronger, as 
indicated by a 0.115 Å shorter O'…H distance and a 0.096 Å shorter O'…O distance. AIM-
calculated BCP properties show that the OH bonds in PhOH and MeOH are of a covalent nature, 
having large negative Laplacians. However, the O'…H hydrogen bonds in both systems are by 
definition of a closed-shell (electrostatic) nature, since they have positive Laplacians. They also 
exhibit what is called partial covalence, due to a negative H(r), which is 230% larger in the Tyr 
than in the Ser/Thr model system. The charge densities r(r) and electronic kinetic and potential 
energy densities G(r) and V(r) are also larger (30-45%) in the hydrogenbond in the Tyr versus 
Ser/Thr model system, meaning a stronger H-bond with the Tyr model. To help confirm this,  
we carried out two additional sets of calculations, using a difluoromethylene phosphonate 
CHF2(HPO3)- to model AppCCl2p, and [(MeO)2PO2]- to model ApppI. The optimized structures 
are shown in Figure 4.6c and 4.6d.  All computed properties were very similar to those found 
with the initial models (Table S3), confirming that the phosphonate hydrogen bond in the Tyr 
model is much stronger than in the Ser/Thr model. An atomic charge analysis shows that the 
charge on PhOH in the complexes is ~65% more negative than that for MeOH, due to the 
stronger ability of the phenyl ring to delocalize charge from the Me(HPO3)- or CHF2(HPO3)- 
species, providing in essence, additional resonance stabilization that again contributes to a 
stronger interaction with Tyr.  
Another way to view these interactions is to consider the 1H NMR chemical shifts of the 
protons involved in hydrogen bonding (Table 4.3), as we have reported previously,27, 29 in which 
partial covalence occurs when 1H NMR shifts in hydrogen bonded systems reach the 12-14 ppm 
range (downfield from TMS), while fully shared-electron (covalent) interactions have shifts of 
~21 ppm.29 With the Tyr models, the computed chemical shifts (~12-13 ppm) are much larger 
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than those of the proton involved in the hydrogen bond in the Ser/Thr model (~6-7 ppm), 
consistent with the onset of partial covalence, and these ~12-13 ppm shifts are very similar to 
those we have found in intra-molecular hydrogen bonds in salicylates.27 So: the Tyr versus 
Ser/Thr selectivity effects seen with AppCCl2p are consistent with stronger hydrogen bonding to 
Tyr, which we compute to be DE ~3.9 kcal mol-1 larger than in the Ser/Thr model. A frequency 
analysis was then used to verify the nature of the stationary points on the respective potential 
energy surfaces, yielding a DDG (at 300 K, 1 atm) of 2.85 kcal mol-1, corresponding to a ~100x 
increase in binding to Tyr. With ApppI, kinase inhibition is very much weaker, likely due to 
steric repulsions of the bulky isopentenyl group with Tyr or Ser/Thr, an effect that would of 
course be largest with the more bulky Tyr. 
4.3.5 Synthesis of Novel AppXp Analogs, and Kinase Inhibition. 
Given that there are several kinases that are inhibited by AppCCl2p, the question arises: 
can more potent species be developed? In the case of bone resorption, the NBP zoledronate is a 
very effective drug, but there are numerous cases of bisphosphonate-related osteonecrosis of the 
jaw and it has been suggested that new NNBPs with anti-inflammatory activity might help 
decrease this risk.23f The anti-inflammatory activity of NNBPs is also of interest given their 
potent JAK2 and JAK3 inhibition, plus, tiludronate has been shown to reduce cytokine 
production from activated macrophages,23a to alleviate cachexia in nude mice xenograft 
models,23d and is reported to be effective in treating erosive osteoarthritis of the hand23g as well 
as knee osteoarthritis23e effects that might all be improved with more active/bioavailable species. 
Plus, in the case of anti-cancer activity, kinases might also be targets for NNBP pre-prodrugs13 
that form AppXp inhibitors. For example, we find that the activity of AppCCl2p against wild 
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type EGFR is IC50 ~250 nM, but against 5 mutants, we find d746-750, 4.3 µM; G719S, 760 nM; 
L858R, 490 nM; T790M, 270 nM; L858R, T790M, 80 nM, Table 4.4 and Figure 4.4. 
Since AppCCl2p is a relatively potent inhibitor of the L858R, T790M double mutant and 
since this an important drug target, we elected to synthesize a series of AppCCl2p 
analogs and test them against the EGFR, as well as against the L858R, T790M mutant. We 
synthesized 8 analogs (16-23; Figure 4.8) containing small substituents at the carbon bridging Pb 
and Pg, as well as 4 analogs (5, 24-26) containing larger, aryl substituents. The dibromobenzyl 
species 25 was of interest since the parent bisphosphonate esters were previously shown13a to 
have potent activity against three human tumor cell lines. As with tiludronate, the “protected" 
dibromobenzyl ester bisphosphonate was converted in cells to the AppXp analog 25, as shown in 
the MS and LC-MS results in Figure 4.9. All EGFR IC50 values are in Table 4.5. The most potent 
EGFR inhibitors have CFCl, CCl2, CBr2, or C(Me)N3 bridging groups between Pb and Pg, and 
there is a parabolic dependence of activity on the van der Waals' surface area of the molecules 
(Figure 4.10a). There is also a strong correlation between the pIC50 values for EGFR versus 
EGFR (L858R, T790M) inhibition for n = 13 compounds, with an R = 0.96 (Figure 4.10b), the 
most active compounds (23) being the dibromo-analog of clodronate and (21) the methyl-azide, 
which inhibit the double mutant with IC50 values of 16 nM and 4 nM, respectively. 
The results shown in Table 4.5 and Figure 4.10a indicate that there are several 
contributors to EGFR inhibition by these AppXp species. The most potent inhibitors have highly 
electron-withdrawing substituents on the bridging carbon. This results in a pKa4 of 7.0 for 
AppCCl2p,31 essentially the same as the 7.1 found with ATP,31 while the pKa4  of the CH2 analog 
16 is 8.4, meaning qualitatively that protein electrostatic interactions with AppCCl2p will  mimic 
those found with the ATP substrate. Plus, the phosphonate (O-)…HO (Tyr) interaction will be 
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favored (at least, at pH~7). Why then are some AppXp inhibitors better than others? What the 
parabolic dependence of IC50 on van der Waals' surface area shows is that activity initially 
increases with the size of the bridging carbon substituents, with the CMeN3 and CBr2 species 
having most activity, presumably due to increased hydrophobic interactions.  However, on 
addition of a very large (aryl) substituent, activity decreases, due to the onset of steric repulsions 
with the protein in addition to changes in the pKa4 values and decreased electrostatic/hydrogen 
bonding interactions. Consistent with the EGFR inhibition results, we find low activity with both 
the tiludronate and dibromobenzyl analogs (5, 25) in other kinase assays. The questions then 
arise: what activity do the parent bisphosphonate pro-drugs, as well as pre-prodrug analogs, have 
in cells?		
4.3.6 Cell and Organelle Activity of NNBPs, AppXps, and AppXp Pre-Prodrugs.  
We next sought to see how the clodronate-analog bisphosphonates and their pre-prodrug 
forms 27-33 (Figure 4.11) inhibited tumor cell growth, as well as how the corresponding AppXp 
analogues inhibited the ANT (as measured via mitochondrial respiration). The smaller 
bisphosphonates had very poor cell (H460) growth inhibition activity, with IC50 values of ~500 
µM. This improved with the addition of an aromatic side-chain, the dibromobenzyl 
bisphosphonate having an IC50~26 µM. However, major increases in activity were only found 
with the pre-prodrug species (27-33), as shown in Figure 4.11, with the pivaloyloxymethylene 
(Piv) esters and the phosphoramidate analogs of clodronate13b, 13c all having IC50 values in the 
0.4-6 µM range. But how do the protected NNBPs–that is, their AppXp products actually kill 
cells? 
It has been generally thought that the AppXp analogs of the NNBPs target the ANT, the 
adeninine-nucleotide translocase, with Lehenkari et al.7 reporting that the ANT was inhibited by 
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AppCCl2p with an IC50 of ~50 µM and that mitochondrial respiration was likewise inhibited. We 
thus tested each of the 13 AppXp analogs as well as ApppI in a heart mitochondrial O2-
consumption assay: representative results are shown in Figure 4.12. The range in IC50 values was 
small 0.76 to 6.4 µM (Figure 4.12), and since concentrations of AppCCl2p in treated cells are 
typically in the 100s µM range, then ANT inhibition of mitochondrial respiration is clearly one 
target for all of the NNBP pre-prodrugs. However, in some cases, effects on respiration may be 
minor when compared with effects on kinase inhibition.  
4.3.7 Western Blot Evidence for Effects on Cell Signaling Pathways. 
We next sought to determine whether the Piv-ester of the dibromo analog of clodronate, 
31, had any	effects on cell signaling pathways since 31 was a potent NNBP pre-prodrug and its 
product 23 (Scheme 4.1) was a 100 nM EGFR inhibitor (Table 4.5). We began by screening for 
effects on cell signaling pathways in MCF-7 cells because MCF-7 is a high producer of 
AppCCl2p from clodronate. Since it seemed possible that multiple kinases and pathways might 
be targeted, we elected to first investigate the downstream proteins mTOR and p70S6K, chosen 
because of their central role in many signaling pathways, including osteoclast survival,32 using 
Western blots.  As can be seen in Figures 4.13a-4.13c, the Western blot results in MCF-7 cells 
show inhibition (IC50~6-13 µM) of mTOR and p70S6K phosphorylation, so the NNBP pre-
prodrug 31 (active metabolite AppCBr2p, 23) does affect signaling pathways in MCF-7 cells 
(which have a low EGFR copy number).  
Next, since our initial idea was that the EGFR might be targeted by AppXp compounds, 
we investigated the EGFR pathway in A431 cells, chosen because EGFR is highly expressed. 
There was little effect of 31 on the auto-phosphorylation of EGFR, so we hypothesized that there 
might be involvement of other kinases (that we previously found were potently inhibited by 
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AppCCl2p in vitro) and chose to investigate the phosphorylation of STAT3 (Signal Transducer 
and Activator of Transcription 3; Figure 4.14). STAT3 is involved in cell growth and apoptosis 
and is phosphorylated by Janus kinases (JAK) and as noted above, we found potent inhibition of 
JAK1, JAK2 and JAK3 by AppCCl2p (Table 4.4). As can be seen in Figure 4.14, there is again a 
dose-dependent inhibition (IC50~7 µM) of STAT3 phosphorylation by 31, as found also with 
clodronate itself in macrophages albeit at a higher inhibitor concentration.33 So, the NNBP pre-
prodrug 31 (and likely the other analogs) can affect both upstream (STAT3) as well as 
downstream (mTOR/p70S6K) signaling pathways, consistent with inhibition of one or more 
kinases. 
4.3.8 Cell and Organelle Activity of NBPs: How do They Work? 
The “standard model” for cell growth inhibition by NBPs has been that FPPS and/or 
GGPPS inhibition34 leads to inhibition of protein prenylation, with ApppI formation and ANT 
inhibition also being of importance. More recently, NBPs have been reported to inhibit the 
EGFR, but there was a dose discrepancy between cell growth and kinase inhibition. To further 
probe the NBP mechanism of action, we investigated cell growth inhibition by the 8 NBPs 
shown in Figure 4.1, compounds that inhibit FPPS and/or GGPPS, in a high-EGFR expressing 
cell line, MDA-MB-231.  We measured growth inhibition activity (pEC50=-log10EC50[µM]; dose 
response curves in Figure 4.15), then correlated these effects with EGFR (Table 4.1), FPPS34 and 
GGPPS35 inhibition; GGOH growth inhibition rescue (Figure 4.16); ApppI accumulation (Figure 
4.17), and with clogP, a measure of lipophilicity. Results are summarized in the Pearson R-value 
correlation  matrix/heat map34 shown in Figure 4.18. There was essentially no correlation 
(R~0.09) between NBP-induced cell growth inhibition and EGFR inhibition. There was, 
however, a significant correlation between cell growth inhibition and ApppI levels, R=0.81, as 
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well as with GGPPS inhibition, R=0.75, the GGPPS correlation being almost identical (R=0.8) to 
that we reported previously with a different set of bisphosphonates in a low EGFR expressing 
(MCF-7) cell line.34 The observation that cell growth inhibition correlates with ApppI levels is in 
accord with the work of Mitrofan et al.9b who reported that zoledronate-induced apoptosis 
correlated with high ApppI levels in three cell lines (MCF-7, MDA-MB-436 and RPMI 8226). 
The correlation with GGPPS inhibition supports a prenylation mechanism, while the ApppI 
correlation indicates an ANT mechanism, given that kinase inhibition is so weak. That is, there is 
strong evidence for multiple targeting. While it may seem surprising that we find a much better 
correlation between cell growth inhibition with GGPPS inhibition as opposed to FPPS inhibition 
this is precisely what we found previously with MCF-7 cells and a separate set of 
bisphosphonates,36 with better cell activity being found with the more lipophilic NBPs such as 15 
that have activity against both FPPS and GGPPS, as well as good cell penetration. 
     The observation that there are geranylgeraniol (GGOH) growth inhibition rescues with 
most NBPs has been taken to support a prenylation mechanism. Surprisingly though, Mitrofan et 
al.9b noted that in some cells treated with zoledronate+GGOH (GGOH is converted in cells to 
GGPP), there was essentially no IPP/ApppI production a remarkable observation. They 
suggested that this might be due to negative-feedback regulating HMGCoA reductase activity36-
37 but an alternative or additional explanation for the lack of IPP/ApppI accumulation on 
zoledronate+GGOH treatment is that GGPP in addition to rescuing prenylation-inhibition is a 
potent (~60 nM) inhibitor of mevalonate kinase38 whose inhibition will also block formation of 
isoprenoids. So, inhibiting mevalonate kinase and/or HMGCoAR activity will inhibit formation 
of ApppI and ApppD, meaning that GGOH (or GGPP) can rescue cells from NBP growth 
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inhibition in two ways: First, by providing GGPP for protein prenylation. Second, by blocking 
formation of ApppI/ApppD.  
     The correlation between cell growth inhibition and GGPPS inhibition34 indicates that 
there is a key role for protein geranylgeranylation in cell growth inhibition, as originally reported 
for zoledronate by Goffinet et al.,39 as does the observation that cell growth inhibition is rescued 
by addition of GGOH (Figure 4.18). Moreover, these "rescue" effects are dependent on the 
number of EGFR copies per cell (Figure 4.18b). In these experiments, we used MCF-7, SW620, 
SW480, H460, A549 and MDA-MB-231 cell lines which have increasing EGFR copy numbers 
per cell.40 We find a correlation between GGOH-rescue and EGFR copy	number, most likely 
though an “indirect effect” due to large numbers of EGFR needing to interact with large numbers 
of prenylated Ras proteins to function as opposed to any direct EGFR interaction with the 
bisphosphonates or ApppI/ApppD. Representative correlations between the EGFR copy number 
and the increase in growth inhibition IC50 on GGOH addition for ibandronate, risedronate and 
pamidronate are shown in Figure 4.18b and Figure 4.16. Only very small rescue effects are found 
with pamidronate, consistent with earlier work41 suggesting primary targets other than 
prenylation, for this bisphosphonate.   
     Taken together, the results discussed above indicate: First, NBPs do not significantly 
inhibit the EGFR. Second, there are no EGFR bisphosphonate-inhibition correlations with cell 
activity. Third, some kinases are inhibited by ApppI and ApppD, and cell growth inhibition 
correlates with ApppI levels, but kinase inhibition is weak, so the ANT is a likely target. Fourth, 
the correlation between cell growth inhibition and GGPPS inhibition reflects the importance of 
protein geranylgeranylation. Fifth, there are large increases in GGOH-rescue seen in high EGFR 
copy number cells, but since EGFR inhibition is so weak, this represents an indirect effect, due 
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to the importance of protein prenylation and FPPS/GGPPS inhibition. Sixth, GGOH-rescues can 
have additional mechanisms of action beyond prenylation-rescue since the GGPP that is formed 
in cells from GGOH is a known inhibitor of mevalonate kinase, whose inhibition (together with 
HMGCoAR degradation) will lead to reduced ApppI/ApppD levels. In brief then, all of our 
results support the canonical prenylation+ANT mechanism of action for the NBPs and not the 
kinase-inhibition mechanism, although for the NNBPs, our results do support an ANT+kinase 
mechanism. There is, therefore, multi-targeting for both NBPs as well as NNBPs. Interestingly, 
“ApXpp” compounds (in which the Pb-O-Pg bridging oxygen is replaced by e.g. CHF) have 
been reported to act as substrates for kinases such as EGFR and SRC,42 the terminal Pa-O-Pb 
group still being capable of substrate phosphorylation. With X=CHF, there is remarkable ~1000x 
difference in activity between the R and S epimers, although activity was less than that found 
with ATP itself.42 In the AppXp systems, the terminal Pb-X-Pg group is inactive, however, due 
to the presence of two P-C bonds, so these compounds can act as kinase inhibitors. 
4.4 Conclusions 
 The results that we have presented above lead to new views as to the mechanism of 
action of bisphosphonates. Rather than NBPs (like zoledronate) and NNBPs (like clodronate) 
just producing ATP-analogs that target the ANT with NBPs also leading to inhibition of protein 
prenylation, we now see that some ATP-analogs act as kinase inhibitors. Clodronate and its pre-
prodrug forms, for example, are converted in cells to the ATP analog AppCCl2p that we find to 
be a low nM inhibitor of kinases such as PDGFRa, JAKs, and FGFR2, as well as being an ANT 
inhibitor. Our 369-kinase kinome screen and dose-response results indicate that JAK3 is the 
kinase that is most potently inhibited by AppCCl2p, of interest since JAK3 is the target for 
tofacitinib, a potent anti-inflammatory drug, and as discussed above, some NNBPs have anti-
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inflammatory activity.  The JAK/STAT/Tyk2 pathways are targeted by cytokines and are 
involved in e.g. rheumatoid arthritis and of interest here, JAK3 and Tyk2 are inhibited by 
AppCCl2p (at 5 nM and ~230 nM, respectively, as is STAT3 phosphorylation (by 31), 
suggesting a possible mechanism for clodronate (or its analogs) in blocking inflammation by 
targeting the JAK/STAT pathway. Our results also provide evidence that AppCCl2p targets 
tyrosine kinases (~78%) in preference to serine/threonine kinases, and the results of DFT and 
AIM theoretical calculations indicate stronger (~100x) hydrogen-bond interactions between 
AppCCl2p and Tyr versus with Ser/Thr. And finally, the observation that AppXp species are 
kinase inhibitors opens up new possibilities for the development of "pre-prodrugs" using the 
protecting groups (phosphoramidates, pivaloyloxymethylenes, isoproxils) used in antivirals to 














4.5 Figures, Tables, and Scheme 
 



















Figure 4.2. Time-line for proposed bisphosphonate mechanisms of action. (a) In 1969, 
clodronate and etidronate were proposed to affect bone resorption by a “physical” mechanism, 
involving direct bone-binding, inhibiting hydroxyapatite dissolution. (b) In 1992, clodronate and 
etidronate were shown to be converted to AppCCl2p in the slime mold Dictyostelium discoideum, 
a model for osteoclasts. (c) In 1999, next generation NBPs such as risedronate were shown to 
block protein prenylation by inhibiting farnesyl diphosphate synthase. (d) In 2002, it was shown 
that AppCCl2p inhibited the mitochondrial adenine nucleotide translocase (ANT). (e) In 2009, it 
was shown that NBPs such as zoledronate led to accumulation of isopentenyl diphosphate and 
dimethylallyl diphosphate which were then converted to ApppI and ApppD, with ApppI being 
found to inhibit the ANT. (f) In 2015, it was reported that NBPs such as risedronate and 










Table 4.1. IC50 values for EGFR inhibition by bisphosphonates, phosphonate-containing ATP 




































Figure 4.3. Representative dose-response curves for EGFR inhibition by bisphosphonates, ATP-
analogs and known EGFR inhibitors. Results are rank-ordered by decreasing activity. IC50 values 
are in moles L-1. 
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JAK3	 1.5E-03	 EGFR	 1.0	
PDGFRa	 0.01	 MST4	 1.5	
JAK2	 0.02	 TYK1/LTK	 1.5	
FGFR2	 0.05	 CDK7/cyclin	H	 1.6	
DDR2	 0.08	 Aurora	B	 1.8	
ABL1	 0.09	 SGK3/SGKL	 2.4	
PKCepsilon	 0.09	 PLK1	 2.6	
JAK1	 0.10	 NEK7	 2.7	
FRK/PTK5	 0.11	 ERBB4/HER4	 2.7	
RET	 0.12	 DLK/MAP3K12	 3.4	
FLT3	 0.12	 ULK3	 3.4	
PKCd	 0.14	 ASK1/MAP3K5	 3.4	
LYN	B	 0.21	 ERN1/IRE1	 3.5	
ABL2/ARG	 0.21	 NEK1	 3.9	
EGFR	 0.21	 PKCtheta	 3.9	
DYRK3	 0.22	 P38d/MAPK13	 4.0	
JNK2	 0.23	 ROS/ROS1	 4.0	
TYK2	 0.23	 STK25/YSK1	 4.1	
FGFR1	 0.24	 GSK3b	 4.3	















10-point dose response curve 
(log IC50 µM) 
single point kinome screen 
(log IC50 µM) 
PDGFRa -2.38 -2 
JAK3 -2.3 -2.82 
JAK2 -1.9 -1.7 
FGFR2 -1.65 -1.28 
PKCepsilon -1.36 -1.05 
DDR2 -1.32 -1.11 
JAK1 -1.18 -1 
ABL1 -1.1 -1.05 
FRK/PTK5 -0.99 -0.96 
RET -0.86 -0.92 
EGFR -0.19 -0.68 
PKCa 0 -0.02 
MEK1 0.08 -0.03 
IKKa/CHUK 0.72 0.17 
AKT1 0.8 0.59 
BRAF 0.89 0.31 
RAF1 1.23 0.62 
 
Figure 4.4.  Estimated IC50 from Kinome screen is correlated to the IC50 from 10-point dose 
response curve. (a) Graph showing the correlation between the log10IC50 values estimated from 
the kinome screen and those determined from the 10-point dose-response curves. The R-value is 







Figure 4.5. Kinase inhibition results for AppCCl2p (4) and ApppI (11) mapped onto a Kinmap 
dendrogram showing more potent and selective Tyr-kinase inhibition by AppCCl2p. (a) Kinmap 
dendrogram for AppCCl2p. (b) Kinmap dendrogram for ApppI. The size of the circle was set in 
Kinmap as 100+(50*pIC50 [µM]) so the larger the circle, the lower the IC50. Red = Tyr kinase; 
Cyan = Ser/Thr kinase. AppCCl2p inhibits almost exclusively Tyr-kinases but ApppI inhibits a 










Figure 4.6. Schematic illustration of tautomerism with a phenol/phosphonate, and geometry-
optimized structures. (a) Tautomerism in a phenol/phosphonate hydrogen bond. (b) Geometry-
optimized structures of phenol or methanol with methyl phosphonate. (c) As (b) but phenol or 
methanol with difluoromethyl phosphonate. (d) Phenol or methanol with a difluoromethyl 


































Table 4.3. Computed bond lengths, bond angles, bond critical point properties and 1H NMR 
chemical shifts for phosphonate-Tyr and phosphonate-Ser/Thr models 
 Bond ROH ROO' ÐOHO' dH DdH
 a r (r) L(r) G(r) V(r) H(r) 
(Å) (Å) (°) (ppm) (ppm) (au) (au) (au) (au) (au) 
PhOH·Me(HPO3)- O'···H 1.592 2.597 176.8 13.01 9.42 0.0562 0.1343 0.0424 -0.0513 -0.0089 
 O-H 1.006     0.3179 -2.3444 0.0692 -0.7244 -0.6553 
MeOH·Me(HPO3)- O'···H 1.707 2.693 176.5 6.76 7.63 0.0418 0.1200 0.0327 -0.0353 -0.0027 
 O-H 0.987     0.3410 -2.5457 0.0707 -0.7779 -0.7072 
PhOH· CHF2(HPO3)- O'···H 1.649 2.644 178.7 11.88 8.29 0.0482 0.1272 0.0371 -0.0423 -0.0053 
 O-H 0.995     0.3297 -2.4714 0.0680 -0.7538 -0.6858 
MeOH· CHF2(HPO3)- O'···H 1.758 2.738 176.4 5.87 6.74 0.0366 0.1113 0.0289 -0.0299 -0.0011 
 O-H 0.981     0.3481 -2.6104 0.0708 -0.7943 -0.7234 
PhOH· [(MeO)2PO2]- O'···H 1.61 2.611 176.2 12.69 9.10 0.0536 0.1329 0.0408 -0.0484 -0.0076 
 O-H 1.002     0.3218 -2.3872 0.0689 -0.7346 -0.6657 
MeOH· [(MeO)2PO2]- O'···H 1.717 2.701 177.9 6.56 7.43 0.0407 0.1195 0.0321 -0.0344 -0.0023 
 O-H 0.985     0.3435 -2.5662 0.0711 -0.7837 -0.7126 
















Table 4.4. Dose-response IC50 values for AppCCl2p inhibition of 18 kinasesa 
	
Kinase	 IC50	 Kinase	 IC50	
PDGFRa	 4	nM	 FRK/PTK5	 100	nM	
JAK3	 5	nM	 RET	 140	nM	
JAK2	 13	nM	 EGFR	(T790M)	 270	nM	
FGFR2	 22	nM	 EGFR	(L858R)	 490	nM	
PKCepsilon	 43	nM	 EGFR	 560	nM	
DDR2	 47	nM	 EGFR	(G719S)	 760	nM	
JAK1	 66	nM	 EGFR	(d746-750)	 4.3	µM	









































































16, X=CH2; 17, X=CHF; 18, X=CF2; 19, X=CFCl; 20, X=CFBr; 
21, X=CMeN3; 22, X=CClBr; 23, X=CBr2; 24, X=CHOC6H4-p-Cl; 
25, X=CHCH2C6H3-m,p-Br2; 26, X= CHSC6H3-m,p-Br2
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Figure 4.9. Conversion in MDA-MB-231 cells of the tetrakis-pivaloyloxymethylene ester of 
dibromobenzylmethylene bisphosphonate 27 into the 1R, 1S epimers of 25. (a) High-resolution 
extracted-ion mass spectrum of 25. (b) Liquid chromatogram results showing 2 peaks, 





Table 4.5. Inhibition of EGFR and EGFR (L858R, T790M) by AppXps, together with 
computed van der Waals’ surface areas 
Compound VSA, (Å2) EGFR IC50 (µM) EGFR (L858R, T790M) IC50 (µM) 
16 172 29 10 
17 176 19 3.5 
18 180 11 2 
19 187 0.11 0.02 
20 190 2.2 0.26 
4 193 0.42±0.2 0.06±0.03 
21 194 0.064 0.004 
22 197 1.3 0.17 
23 201   0.12 0.016 
24 223 3 2 
5 228 7.1 1.1 
25 242 20 19 

















Figure 4.10. EGFR inhibition by AppXp analogs. (a) Parabolic fit of EGFR inhibition versus the 
van der Waals’ surface area (VSA); R=0.78. (b) Correlation between WT EGFR inhibition and 
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Figure 4.13. Western blot results for effects of 31 on mTOR and p70S6K phosphorylation. The 
stacked plots are summed photo-densitometer traces; representative gels are shown below, and 
dose-response curves and IC50 values (from summed intensities of 3 blots) are shown in the 
insets. (a) mTOR in MCF7 cells induced with serum. (b) p70S6K in MCF-7 cells induced with 






































































































Figure 4.15. Inhibition of MDA-MB-231 cell growth by NBPs. Results from three independent 




Figure 4.16. Effects of 20 µM geranylgeraniol (GGOH) on MDA-MB-231 cell growth inhibition 
by bisphosphonates. (a) Data from three independent sets of experiments, fit to single dose-
response curves. The colored bars relate to the controls shown in Figure 4.15. (b) Results 
summarized as the x-fold increases in the EC50 in cells grown in the presence of 20 µM GGOH. 
(c) Bar graph showing the x-fold increase in ED50 with structures of each compound tested. 
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Figure 4.17. LC-MS determination of ApppI concentrations in MDA-MB-231 cells. (a) 
Representative LC-MS chromatogram of an ApppI sample. (b) ApppI calibration curve used to 
calculate ApppI concentrations. (c) ApppI concentrations in MDA-MB-231 cells after BP 














Figure 4.18. Correlations between cell growth inhibition and various properties, and GGOH-
rescue results with three bisphosphonates in different cell lines. (a) Correlation between MD-
MBA-231 cell growth inhibition pEC50 (=-log10 EC50 [µM]) and GGPPS inhibition pIC50; 
GGOH rescue factor (the ratio of the EC50 with or without 20 µM GGOH); clogP; log10[ApppI; 
µM]; FPPS inhibition pIC50 and EGFR pIC50. The numbers shown in the matrix are the Pearson 
R-value correlation coefficients. Green colors highlight strong correlations, yellow are 
intermediate, red indicates no significant correlation. (b) GGOH x-fold rescue of the growth 
inhibition of 6 cell lines for three bisphosphonates as a function of EGFR copy number. The R-
values for two bisphosphonates are high but for pamidronate is not significant. The high 
correlation between cell growth inhibition and GGPPS inhibition (R=0.75) in (a) is very similar 
to that seen previously with MCF-7 cells and other bisphosphonates (R=0.80). The correlation 
between cell growth inhibition and ApppI levels is also very high (R=0.81) and taken together 
these results indicate the importance of multi-targeting with both protein geranylgeranylation as 
well as ApppI/AppppD inhibitors contributing to bisphosphonate activity. 
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